Invitation to Tender – supply of pharmaceuticals to DHB hospitals and/or to community pharmacies (text extract)

This is the text extract for Invitation to Tender – supply of pharmaceuticals to DHB hospitals and/or to community pharmacies, browse documents here.

Contents

Schedule 1: Definitions and interpretation ....................................................................... 4 1. 2. Definitions .................................................................................................................... 4 Interpretation.............................................................................................................. 10

Schedule 2: Products to be tendered .............................................................................. 12 1. 2. Information about Tender Items................................................................................ 12 List of Products.......................................................................................................... 15

Schedule 3: Tender Process ............................................................................................ 49 1. 2. 3. 4. 5. 6. 7. 8. 9. General ....................................................................................................................... 49 Information about submitting a Tender Bid ............................................................. 53 What to include in your Offer Letter and Tender Submission Form....................... 55 How to submit a Tender Bid ...................................................................................... 57 Evaluation................................................................................................................... 57 Conformity.................................................................................................................. 58 Decision...................................................................................................................... 59 Back-up supply .......................................................................................................... 60 Dealing with information ........................................................................................... 61

10. Miscellaneous ............................................................................................................ 61 Schedule 4: Offer Letter, Tender Submission Form Offer Letter................................... 63 1. 2. 3. Guidance for completing the Tender Submission Form ......................................... 63 Offer Letter, Tender Submission Form ..................................................................... 64 Tender Submission Form .......................................................................................... 66

Schedule 5: Contract terms for Hospital Supply Status ................................................ 68 1. 2. 3. 4. 5. 6. 7. 8. General ....................................................................................................................... 68 Effect of Hospital Supply Status ............................................................................... 68 Consents .................................................................................................................... 75 Price ............................................................................................................................ 75 Invoicing and Payment .............................................................................................. 76 Emergency and disaster supply ............................................................................... 77 Defective and short-dated Pharmaceuticals ............................................................ 77 Out-of-stock arrangements ....................................................................................... 78

R33-4-0 #94186

Termination, restrictions and Crown Direction........................................................ 81

10. Guarantee ................................................................................................................... 82 11. Audit............................................................................................................................ 82 12. Access by PHARMAC to price and volume data...................................................... 82 13. PCTs............................................................................................................................ 83 14. Miscellaneous ............................................................................................................ 84 Schedule 6: Contract terms for Sole Supply Status....................................................... 88 1. 2. 3. 4. 5. 6. 7. 8. 9. General ....................................................................................................................... 88 Effect of Sole Supply Status...................................................................................... 89 Consents .................................................................................................................... 91 Price ............................................................................................................................ 92 Shelf-life of Pharmaceutical ...................................................................................... 92 Out-of-stock arrangements ....................................................................................... 93 Termination, restrictions and Crown Direction........................................................ 95 Guarantee ................................................................................................................... 96 Miscellaneous ............................................................................................................ 96

Schedule 7: Additional contract terms for foreign exchange bid.................................. 99 1. 2. 3. 4. 5. Introduction ................................................................................................................ 99 Establishment of Base Price in New Zealand dollars. ............................................. 99 Exchange Rate Price Review................................................................................... 100 Reviewed Price......................................................................................................... 100 Dispute Over Price ................................................................................................... 101

R33-4-0 #94186

Schedule 1

Schedule 1: Definitions and interpretation

Definitions

In this Invitation: Aggregated Tender Bid means a Tender Bid for more than one Tender Item, which: (a) (b) PHARMAC is to consider in aggregate; and is specified to be an Aggregated Tender Bid,

and can include a Tender Bid for more than one Tender Item of the same Chemical Entity but not aggregation within a single Tender Item; Agreement means: (a) (b) in relation to a Pharmaceutical with Hospital Supply Status, Schedule Five; or in relation to a Pharmaceutical with Sole Supply Status, Schedule Six,

and includes, to the extent applicable, the other Schedules comprising the Invitation; Alternative Pharmaceutical means an alternative brand of a Pharmaceutical that PHARMAC, following consultation with HPAC, or PTAC or its sub-committees, considers to be an acceptable substitute for that Pharmaceutical; Back-up Supply Agreement means an alternative agreement or arrangement negotiated by PHARMAC, at its sole discretion, with a supplier other than the supplier with Sole Supply Status and/or Hospital Supply Status in respect of a particular Tender Item, to cover the contingency that Sole Supply Status and/or Hospital Supply Status is suspended or withdrawn under the terms of this Agreement in respect of that Tender Item, or that the Tender Item is otherwise out of stock or unavailable for supply; Base Exchange Rate means the average of the Reserve Bank Quote over 10 consecutive trading days ending: (a) in the case of an unconditional acceptance of your Tender Bid, 15 days prior to the date that PHARMAC’s board of directors (or chief executive, where applicable) determines to accept your Tender Bid; or in the case of acceptance of your Tender Bid being conditional on you obtaining market approval for the Pharmaceutical, on the date on which such market approval is notified in the New Zealand Gazette;

(b)

Base Price means, where your Foreign Exchange Bid has been accepted, the price exmanufacturer (exclusive of GST) for the Pharmaceutical, as calculated and notified to you by PHARMAC in accordance with clause 2 of Schedule Seven; Calculated Price is as defined in clause 3 of Schedule Seven; Chemical Entity means any pharmaceutical that contains, and is described generically according to, the relevant active ingredient specified in Schedule Two; Combined Community/Hospital Tender Bid means a Community Tender Bid and a Hospital Tender Bid that you submit in combination for the same Tender Item;

R33-4-0 #94186 4

Schedule 1 Community Tender Bid means a Tender Bid in relation to community supply; Confidential Information means all information exchanged between us under this Invitation or in relation to your Tender Bid, including during all negotiations relating to your Tender Bid; Consents means all consents, permits, licences and authorisations, whether statutory or otherwise, required for the supply of the Tender Item in New Zealand (including Ministry of Health market approval or, in respect of a Tender Item that is a Vitamin, approval by the Therapeutics Goods Administration as either a registrable (AUST R) good or a listable (AUST L) good); Contract Manufacturer means a manufacturer or a supplier that is a party to a contract with the relevant DHB Hospital to compound Pharmaceuticals, on request from that DHB Hospital; Crown Direction means any ministerial direction given to PHARMAC under section 103 of the Crown Entities Act 2004; Date of an Exchange Rate Price Review means 30 June 2007 and 30 June 2008; Deadline means 5 pm, Monday, 27 February 2006 (New Zealand time); Designated Delivery Point means at a DHB Hospital’s discretion: (a) (b) a delivery point agreed between you and the relevant DHB Hospital, to which delivery point you must supply the Pharmaceutical directly at the Price; and/or any delivery point designated by the relevant DHB Hospital or PHARMAC, such delivery point being within 30km of your national distribution centre;

DHB Hospital means a DHB, including its hospital or associated provider unit for which that DHB purchases pharmaceuticals; District Health Board (or DHB) has the same meaning as in the New Zealand Public Health and Disability Act 2000; DV Limit means, for a particular Pharmaceutical, the National DV Limit or the Individual DV Limit; DV Pharmaceutical means a discretionary variance Pharmaceutical, being an Alternative Pharmaceutical that does not have Hospital Supply Status, and includes a pharmaceutical which (unless PHARMAC specifies otherwise in Schedule Two of this Agreement, or we agree otherwise in writing): (a) is listed as a DV Pharmaceutical, in association with the relevant Pharmaceutical having Hospital Supply Status, in the then current Section H of the Pharmaceutical Schedule; or is the same Chemical Entity, at the same strength, and in the same or a similar presentation or form, as the relevant Pharmaceutical with Hospital Supply Status, but which is not yet listed as a DV Pharmaceutical.

(b)

For the avoidance of doubt, a pharmaceutical which: (c) is a different Chemical Entity from the Pharmaceutical with Hospital Supply Status; and

R33-4-0 #94186

Schedule 1 (d) is not listed as a DV Pharmaceutical in the then current Section H of the Pharmaceutical Schedule,

is not a DV Pharmaceutical; End Date means the last day of the Hospital Supply Status Period, or Sole Supply Period, as applicable; Evaluation Committee means a committee established by PHARMAC to evaluate Tender Bids; Exchange Rate Average means the average of the Reserve Bank Quote, over the period: (a) (b) for the first Exchange Rate Price Review, from the date on which the Base Exchange Rate is determined until the first occurring 30 June after that date; and for any subsequent Exchange Rate Price Review, from the date on which the last Exchange Rate Price Review occurred until the date of the next Exchange Rate Price Review;

Exchange Rate Price Review means the review of the Base Price or the Reviewed Price, as applicable, in accordance with clause 3 of Schedule Seven; Final Transition Period means, in respect of a Pharmaceutical with Sole Supply Status or Hospital Supply Status, as applicable, the period of three calendar months beginning on the day after the relevant End Date; First Transition Period means, in respect of a Pharmaceutical with Sole Supply Status or Hospital Supply Status, the period beginning on the first day of the month following the Market Notification Date and ending on the last day of the month following the month in which the Start Date occurs (or such different or longer period as PHARMAC determines under clause 1.2 of Schedule Three); Foreign Exchange Bid means a Tender Bid that specifies a price in a Permitted Currency; Funder means the body or bodies responsible, pursuant to the New Zealand Public Health and Disability Act 2000, for the funding of pharmaceuticals listed on the Pharmaceutical Schedule (which may be, without limitation, one or more District Health Boards and/or the Ministry of Health) and their successors; Hospital Pharmaceuticals Supplement means a supplement that clarifies the application of PHARMAC’s OPPs in respect of hospital pharmaceuticals; Hospital Supply Status means the status of being the brand of the relevant Pharmaceutical listed in Section H of the Pharmaceutical Schedule as having such status, which Pharmaceutical DHB Hospitals must purchase, subject to any DV Limit for that Pharmaceutical, for the Hospital Supply Status Period; Hospital Supply Status Period means the period beginning on the day after the end of the First Transition Period and ending on 30 June 2009; Hospital Tender Bid means a Tender Bid in relation to Hospital Supply; HPAC means the Hospital Pharmaceutical Advisory Committee; IMM means interchangeable multi-source medicine, as defined by the New Zealand Medicines and Medical Devices Safety Authority (Medsafe); Individual DV Limit means, for:

R33-4-0 #94186 6

Schedule 1 (a) (b) a particular Pharmaceutical; and a particular DHB Hospital,

the discretionary variance limit, being a percentage of the Individual Total Market Volume, which equals the percentage of the National DV Limit for that Pharmaceutical, up to which that DHB Hospital may purchase DV Pharmaceuticals of that Pharmaceutical. The Individual DV Limit is set: (c) (d) for the number of months during which the Hospital Supply Status Period applies during the period ending on 30 June 2007; and for the respective 12 month periods ending on 30 June 2008 and 2009;

Individual Total Market Volume means for: (a) (b) a particular Pharmaceutical; and a particular DHB Hospital,

in any given period, in accordance with data available to PHARMAC, the sum of: (c) (d) the total number of Units of the relevant Pharmaceutical with Hospital Supply Status purchased by the relevant DHB Hospital; and the total number of Units of all the relevant DV Pharmaceuticals, listed in Section H in association with that Pharmaceutical, purchased by that DHB Hospital;

Initial Period is as defined in clause 5 of Schedule Seven; Invitation means this invitation to tender and includes the cover letter and each of the Schedules; Lead Time means the length of time indicated on your Tender Bid that, if your Tender Bid is accepted, you would require following the Successful Tenderer Notification Date in order to source sufficient stock of your brand of the Tender Item to meet the market demand for the Tender Item, which must be at least one month; Market Notification Date means the date on which PHARMAC notifies the market that your Tender Bid, in respect of a particular Tender Item, has been accepted, being greater than one month prior to the Start Date; National DV Limit means, for a particular Pharmaceutical, the discretionary variance limit, being the specified percentage of the National Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Pharmaceutical. The National DV Limit is set for DHB Hospitals nationally: (a) (b) for the number of months during which the Hospital Supply Status Period applies during the period ending on 30 June 2007; and for the respective 12 month periods ending on 30 June 2008 and 2009;

National Total Market Volume means, for a particular Pharmaceutical in any given period, in accordance with data available to PHARMAC, the sum of: (a) the total number of Units of the relevant Pharmaceutical with Hospital Supply Status purchased by all DHB Hospitals; and

R33-4-0 #94186

Schedule 1 (b) the total number of Units of all the relevant DV Pharmaceuticals, listed in Section H in association with that Pharmaceutical, purchased by all DHB Hospitals;

Offer Letter means the letter of offer to which your Tender Submission Form(s) must be attached, in the form set out in Schedule Four; OPPs means PHARMAC’s then current Operating Policies and Procedures and any relevant supplements, including the Hospital Pharmaceuticals Supplement, as applicable; PCT means a Tender Item for which a “PCT” is indicated in the list in clause 2 of Schedule Two; Permitted Currency means either United States dollars, the euro, pounds sterling, Australian dollars or Japanese yen; Pharmaceutical means the relevant Tender Item for which you have submitted, and PHARMAC has accepted on behalf of the Funder, a Tender Bid; Pharmacode means the unique six or seven digit identifier assigned to a pharmaceutical and notified to you by the Pharmacy Guild; Potential Out-of-Stock Event means: (a) in relation to community or hospital supply, your stock of the Pharmaceutical in New Zealand falls below two-thirds of your most recent three months’ total Unit sales of the Tender Item; or in relation to community or hospital supply, your forecast of sales demand in respect of the next two-month period is greater than your stock of the Pharmaceutical; or in relation to hospital supply, your stock of the Pharmaceutical in New Zealand falls below the average volume of stock of the Pharmaceutical required to supply the entire New Zealand DHB Hospital market for the Pharmaceutical for any given two-month period; or in relation to community supply, your stock of the Pharmaceutical in New Zealand falls below one-sixth of the Unit Volume.

(b) (c)

(d)

For the avoidance of doubt, references to your stock refer to stock physically held by you or on your behalf in New Zealand and do not include stock held in New Zealand by wholesalers or other parties; Price means the price (exclusive of GST) at which the Pharmaceutical is to be supplied, or made available for sale and supply, by you to: (a) in relation to community supply, wholesalers and other such distributors, and at which the Pharmaceutical is to be subsidised by the Funder, being the price specified in your successful Tender Submission Form, unless there has been a subsequent price change in accordance with the terms of the Invitation, in which case the Price will be the price notified to you by PHARMAC upon acceptance of your Tender Bid; in relation to hospital supply, at a DHB Hospital' discretion, any Designated Delivery s Points, and/or Contract Manufacturers (expressly for the purpose of compounding), being the price specified in your successful Tender Submission Form, unless there has been a subsequent price change in accordance with the terms of the Invitation, in which case the Price will be the price notified to you by PHARMAC upon acceptance of your Tender Bid; or

(b)

R33-4-0 #94186

Schedule 1 (c) in the case of a Foreign Exchange Bid, a price determined and notified in accordance with Schedule Seven;

PTAC means the Pharmacology and Therapeutics Advisory Committee; Reserve Bank Quote means the exchange rate between New Zealand dollars and the Permitted Currency in which you made the Foreign Exchange Bid, being the mid rate of the buy and sell quotes for that exchange rate quoted by the Reserve Bank of New Zealand on the days on which the New Zealand dollar and the Permitted Currency are traded, expressed as the value of one New Zealand dollar in Permitted Currency units (e.g. NZ$1.00 = US$[0.64]); Reviewed Price is as defined in clause 4 of Schedule Seven; Risk Sharing Percentage means, in respect of each Tender Item for which you submit a Foreign Exchange Bid, the percentage value of the exchange rate risk (between 1% and 100%) that you agree to share with PHARMAC for that Tender Item. For example, if you specify an 80% Risk Sharing Percentage, you agree that 80% of the price at which you supply the Tender Item may change in response to foreign exchange movement and 20% of the price will not change, in accordance with the terms in Schedule Seven; Second Transition Period means, in relation to community supply, the period of three calendar months beginning on the day after the expiry of the First Transition Period (or such different or longer period as PHARMAC determines under clause 1.2 of Schedule Three); Section H means the relevant section or sections of the Pharmaceutical Schedule relating to hospital pharmaceuticals; Sole Supply Period means the period beginning on the day after the expiry of the Second Transition Period and ending on 30 June 2009; Sole Supply Status means, in relation to community supply, the status of being the sole subsidised supplier of the particular Tender Item for the Sole Supply Period; Start Date means: (a) in relation to a Tender Item for which your Tender Bid has been accepted unconditionally, the first day of the month following the date that represents: (i) (ii) (b) the Successful Tenderer Notification Date; plus the Lead Time; or

in relation to a Tender Item for which your Tender Bid has received conditional acceptance, in terms of clause 7.4 of Schedule Three, the first day of the month following the date that represents: (i) (ii) the date that such acceptance ceases to be conditional; plus the Lead Time; or

(c)

such other date that is negotiated between you and PHARMAC under clause 1.6 of Schedule Three;

Successful Tenderer Notification Date means the date on which PHARMAC notifies you, in relation to a Tender Item for which you have submitted a Tender Bid, that your Tender Bid has been accepted;

R33-4-0 #94186 9

Schedule 1 Tender Bid means the Offer Letter together with the Tender Submission Form submitted for a particular Tender Item, including the Lead Time, and includes a Community Tender Bid, a Hospital Tender Bid and a Combined Community/Hospital Tender Bid; Tender Item means the form and strength of a Chemical Entity (or entities, if applicable) for which you may submit a Tender Bid; Tender Submission Form means the form on which you must submit your bid for each Tender Item and which is attached to the Offer Letter, as set out in Schedule Four; Transition Periods collectively refers to the First, and Second (if applicable), and Final Transition Periods; Unit means an individual unit of a Tender Item (e.g. tablet, 1ml of an oral liquid, ampoule, syringe); Unit Price means the relevant Price specified for a pack of that Tender Item in Section H of the Pharmaceutical Schedule, divided by the number of Units in the pack specified in the Pharmaceutical Schedule as being the listed pack size for that Tender Item (and where that Tender Item is not listed on the Pharmaceutical Schedule, the price and pack size in the most recent issue of the Pharmaceutical Schedule published prior to that Tender Item being delisted); Unit Subsidy means the subsidy specified for a pack of that Tender Item in sections A to G of the Pharmaceutical Schedule, divided by the number of Units in the pack specified in the Pharmaceutical Schedule as being the subsidised pack size for that Tender Item (and where that Tender Item is not listed on the Pharmaceutical Schedule, the subsidy and pack size specified in the most recent issue of the Pharmaceutical Schedule published prior to that Tender Item being delisted); Unit Volume means, in relation to community supply, the approximate number of Units of the Tender Item subsidised by PHARMAC, and claimed for by community pharmacies, in one year, as specified in Schedule Two; and Vitamin means a Tender Item for which a “V” is indicated in the list in clause 2 of Schedule Two.

Interpretation

In the construction of this Invitation, unless the context otherwise requires: (a) (b) a reference to a clause or a Schedule is a reference to a clause of, or a Schedule to, this Invitation; a reference to a statute or other law includes regulations and other instruments under it and consolidations, amendments, re-enactments or replacements of any of them (whether before or after the date of this Agreement); the singular includes the plural and vice versa; the word person includes an individual, a body corporate, an association of persons (whether corporate or not), a trust, a state and an agency of state, in each case, whether or not having a separate legal personality; a reference to a person includes a reference to the person’s executors, administrators, successors, substitutes, (including, but not limited to, persons taking by novation) and permitted assignees;

(e)

R33-4-0 #94186

Schedule 1 (f) (g) (h) words importing one gender include the other genders; headings in this Agreement are for convenience only and have no legal effect; and unless the context requires otherwise, references to the “listing” of a Pharmaceutical: (i) in relation to hospital supply, are to the listing of that Pharmaceutical in Section H of the Pharmaceutical Schedule and are deemed to include any written notification by PHARMAC of that Pharmaceutical being the subject of a national supply contract negotiated by PHARMAC on behalf of DHBs, where such written notification is in advance of the actual listing of that Pharmaceutical in Section H of the Pharmaceutical Schedule (and references to “list”, “listed”, “delisted”, and “delisting” are to be interpreted accordingly); in relation to community supply, are to the actual listing of that Pharmaceutical in sections A to G of the Pharmaceutical Schedule.

(ii)

R33-4-0 #94186

Schedule 2

Schedule 2: Products to be tendered

1.1

Information about Tender Items List of Tender Items

This Schedule sets out the Tender Items and information about the Tender Items. While PHARMAC has taken all reasonable care in preparing the information contained in this Schedule, it accepts no liability for any errors or omissions in the information.

1.2

Patents

(a) (b) (c) Where possible, PHARMAC has identified Tender Items that it understands may be the subject of a patent that it believes is due to expire after the Deadline. Where PHARMAC has been advised of the existence of a process patent prior to sending out this Invitation, it has shown this in the attached list by the use of a + symbol. However, PHARMAC makes no representation as to the patent status of the Tender Items and accepts no liability for any patent infringement that might occur as a result of this tender process or PHARMAC’s acceptance of a Tender Bid, including infringement of process patents.

1.3

Unit Volume and market value figures

(a) (b) Except where indicated otherwise the Unit Volume figures, in relation to community supply, are based on the year ending 30 June 2005. Market value figures, in relation to community supply, are expressed as the Unit Volume in the year ending 30 June 2005, multiplied by the Unit Subsidy as at 1 September 2005. The figures referred to in paragraphs (a) and (b): (i) are approximate and indicative only. PHARMAC makes no representation as to the accuracy of these figures or as to the level of sales or likely sales of any Tender Item. In particular, if these figures change at any time during the period from PHARMAC’s pre-tender consultation until decisions have been made about the acceptance of Tender Bids for all Tender Items, PHARMAC is not obliged to notify you of any such change; may not fully take into account any potential change in subsidised volumes as a result of some pharmaceuticals being dispensed in quantities providing for up to 90 consecutive days'treatment or, in the case of oral contraceptives, up to 180 consecutive days’ treatment (following the partial return to all at once dispensing); and do not include DHB Hospital volumes. For the avoidance of doubt, PHARMAC makes no representation as to the size of the DHB Hospital market for any Tender Item, in relation to hospital supply.

(c)

(ii)

(iii)

(d)

You acknowledge and agree that in submitting your Tender Bid you will rely on your own knowledge, skill and independent advice or assessment of the market size for any Tender Item and PHARMAC is to have no liability in that regard.

R33-4-0 #94186

Schedule 2

1.4

Special terms

Where there are any special terms relating to a particular Tender Item, those terms are indicated in the column entitled “Comments” in the list.

1.5

Subsidies

(a) (b) (c) The level at which each Tender Item, in relation to community supply, is specified in the attached list as being subsidised per Unit is as at 1 September 2005. Subsidies of Tender Items, in relation to community supply, may change before a Tender Bid is accepted. Where a * symbol is indicated next to the Unit Subsidy, there is no fully funded product available, in relation to community supply, for that Tender Item as at 1 September 2005.

1.6

DV Limits

Where there is a DV Limit relating to a particular Tender Item, in relation to hospital supply, that limit is indicated as a percentage amount in the column entitled “DV Limit” in the list.

1.7

Tender Items subject to sole supply arrangements

Where a Tender Item is underlined, that item is subject to a sole supply contract as at the date of this Invitation. Accordingly, the subsidy for those items is fixed until 30 June 2006 (unless otherwise indicated) and, for items that are the subject of a sole supply contract, the listing of a new brand, in relation to community supply, could only occur after that date.

1.8

Hospital only products

Where an H is indicated, you may submit a Tender Bid for Hospital Supply Status for that Tender Item.

1.9

Community only Products

Where a C is indicated, you may submit a Tender Bid for Sole Supply Status for that Tender Item.

1.10

Community and Hospital Products

Where a C and an H is indicated, you may submit a Tender Bid for Sole Supply Status and/or a Tender Bid for Hospital Supply Status for that Tender Item. You may also submit a Combined Community/Hospital Tender Bid in accordance with clause 2.5 of Schedule Three.

1.11

PCTs

Where a “PCT” is indicated, you may submit a Tender Bid for Hospital Supply Status for that Tender Item on the basis that, if PHARMAC accepts your Tender Bid, the Tender Item would be listed in Section H of the Pharmaceutical Schedule subject to clause 13 of Schedule Five.

R33-4-0 #94186

Schedule 2

1.12

IMM status

Where a symbol is indicated, your brand of the relevant Chemical Entity for which you submit a bid must have or be expected to gain IMM status.

1.13

Capsule and tablet form

Where a Tender Item specifies either: (a) (b) a capsule; or a tablet,

form of the Chemical Entity, your brand of the relevant Chemical Entity for which you submit a bid may be in either tablet or capsule form, provided that: (c) (d) your brand of the relevant Chemical Entity is the same strength as the Tender Item; and where the Tender Item specifies both the tablet and capsule form of that Chemical Entity as separate line items, you must submit a bid for the same form and strength as each line item in that Tender Item.

1.14

Pack size for use in DHB Hospitals

Where a Tender Item is specified as being available for a Tender Bid for Hospital Supply Status, it is the preference of DHB Hospitals that the pack size for such a Tender Item is: (a) (b) (c) 500 ml or less, where the Tender Item is in liquid form; 200 tablets or capsules, where the Tender Item is in tablet or capsule form; and 10 injections, where the Tender Item is in injection form.

Notwithstanding the preference of DHB Hospitals for Tender Items to be in pack sizes as specified in paragraphs (a) to (c) above, you may submit, and PHARMAC will consider and may accept, a Tender Bid for any pack size, including larger pack sizes, following its evaluation of Tender Bids under clause 5.2 of Schedule Three.

R33-4-0 #94186

Chemical Name Line Item Abacavir Sulphate Oral liq 20 mg per ml Tab 300 mg Acarbose Tab 50 mg Tab 100 mg Acebutolol Cap 100 mg Cap 200 mg Tab 400 mg Acetazolamide Sodium inj 500 mg

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

3,120 59,712

$1,300 $455,800

$0.4167 $7.6333

+ C H + C H

C H C H

1% 1%

398,135 125,544

$97,304 $43,237

$0.2444 $0.3444

1% 1%

97,700 145,063 36,476

$9,282 $23,123 $10,078

$0.0950 $0.1594 $0.2763

C H C H C H

1% 1% 1%

233

$3,250

$13.9500

C H

Acetic Acid with 1, 2- Propanediol Diacetate and Benzethonium Ear drops 2% with 1, 2-Propanediol diacetate 3 % and benzethonium chloride 0.02 % 85,540 $14,251 $0.1666 C H 1%

Acetic Acid with Boric Acid, Hydroxyquinoline and Ricinoleic Acid Jelly with boric acid 3%, hydroxyquinoline sulphate 0.025% and ricinoleic acid 0.75% with applicator Acetylcysteine Eye drops 5% Inj 200 mg per ml, 10 ml Aciclovir Tab 200 mg C H 1% Dispersible tablets need to

remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly

345,300

$29,109

$0.0843

C H

H 142 $1,946 $13.7060 * C H

1% 1%

Tab 400 mg

C H

1% Dispersible tablets need to

Tab 800 mg

C H

1% Dispersible tablets need to

Tab dispersible 200 mg Tab dispersible 400 mg Tab dispersible 800 mg Inj 250 mg Inj 500 mg Eye oint 3% Adenosine Inj 3 mg per ml, 2 ml Alfacalcidol Cap 0.25 mcg Cap 1 mcg Oral drops 2 mcg per ml Alfentanil Inj 0.5 mg per ml, 2 ml

164,403 2,949,652 575,903

$16,440 $442,448 $153,766

$0.1000 $0.1500 $0.2670

C H C H C H H H

1% 1% 1% 1% 1% 1%

19,552

$163,064

$8.3400

C H

146,074 39,355 8,680

$38,447 $34,625 $26,335

$0.2632 $0.8798 $3.0340

C H C H C H

1% 1% 1%

1% 15

Chemical Name Line Item Allopurinol Inj 200 mg Alpha Tocopheryl Acetate

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

C H

Water solubilised soln 156 iu/ml, with calibrated dropper Alprostadil Inj 0.5 mg per ml, 1 ml Alteplase Inj 10 mg Inj 50 mg Amantadine Hydrochloride Cap 100 mg Amethocaine Gel 4% Amikacin Inj 5 mg per ml, 5 ml Inj 250 mg per ml, 2 ml Amiloride Tab 5 mg Amiodarone Hydrochloride Inj 50 mg per ml, 3 ml Amorolfine Nail soln 5% Amoxycillin Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Amphotericin B Inj 50 mg Lozenges 10 mg Amyl Nitrite Ampoule, 0.3 ml crushable Apomorphine Hydrochloride Inj 10 mg per ml, 1 ml Aprotinin Inj 10,000 mcg per ml 50 ml Arginine Inj 5%, 500 ml Ascorbic Acid Tab 100 mg Tab 250 mg Inj 500 mg Aspirin Tab 300 mg

75,900

$20,493

$0.2700

C H V

H H

1% 1%

365,088

$290,902

$0.7968

C H

H H

1% 1%

511

$3,109

$6.0840

C H

2,435

$18,438

$7.5720

C H

31,325,984 20,271,607

$338,321 $279,748

$0.0108 $0.0138

C H C H

1% 1%

H 181,116 $53,067 $0.2930 C H

1% 1%

160

$839

$5.2433

C H

3,574

$36,047

$10.0860

C H

545

$34,662

$63.6000

C H

1,047,625

$27,238

$0.0260 $0.0862

C H V C H V H

1% 1% 1%

724,173

$19,263

$0.0266

C H

1% Line item does not include

soluble 300 mg tablets

Chemical Name Line Item Aspirin Tab EC 300 mg Tab EC 650 mg Atenolol Tab 50 mg Tab 100 mg Atorvastatin Tab 10 mg Tab 20 mg Tab 40 mg Atropine Sulphate Eye drops 0.5% Inj 400 mcg, 1 ml Inj 600 mcg, 1 ml Inj 1200 mcg, 1 ml Auranofin Tab 3 mg Azithromycin Tab 500 mg Aztreonam Inj 500 mg Inj 1 g Baclofen Oral liq 5 mg per 5 ml Inj 2 mg per ml, 5 ml Beclomethasone Dipropionate

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

1,701,969 1,073

$123,393 $74

$0.0725 $0.0688

C H C

13,222,586 4,202,681

$198,339 $116,835

$0.0150 $0.0278

C H C H

1% 1%

987,970 2,641,586 5,547,366

$144,244 $561,865 $1,636,473

$0.1460 $0.2127 $0.2950

* * *

+ C + C + C

C H C H C H C H 1% Single dose presentation

would not be a DV Pharmaceutical

2,595 957 67,229 4,810

$695 $573 $32,270 $2,881

$0.2680 $0.5990 $0.4800 $0.5990

1% 1% 1%

18,926

$21,761

$1.1498

C H

54,892

$426,236

$7.7650

C H

H H

1% 1%

H H

1% 1%

Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose Bendrofluazide Tab 1.25 mg Tab 2.5 mg Tab 5 mg Benztropine Mesylate Inj 1 mg per ml, 2 ml Tab 2 mg Benzylpenicillin Sodium Inj 600 mg Inj 1.2 g Inj 3 g Beractant Inj 25 mg per ml, 8 ml Betahistine Dihydrochloride Tab 8 mg

9,170,400 29,822,800

$98,123 $334,015

$0.0107 $0.0112

C H C H

1% 1%

C H 24,790,011 2,615,724 $669,330 $112,476 $0.0270 $0.0430 C H C H

1% 1% 1%

2,845 943,671

$20,683 $113,995

$7.2700 $0.1208

C H C H

1% 1%

13,127

$9,176

$0.6990

C H H H

1% 1% 1%

1% 17

Chemical Name Line Item Betamethasone Dipropionate Crm 0.05% Crm 0.05% in propylene glycol base Oint 0.05% Oint 0.05% in propylene glycol base

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

165,205 15,060 169,150 22,560

$32,595 $2,173 $33,373 $3,255

$0.1973 $0.1443 $0.1973 $0.1443

* * * *

C H C H C H C H

1% 1% 1% 1%

Betamethasone Sodium Phosphate with Betamethasone Acetate Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml Betamethasone Valerate Lotn 0.1% Scalp app 0.1% Betamethasone Valerate with Clioquinol Crm 0.1% with clioquinol 3% Oint 0.1% with clioquinol 3% Betamethasone Valerate with Fusidic Acid Crm 0.1% with fusidic acid 2% Bisacodyl Suppos 5 mg Suppos 10 mg Brinzolamide Eye Drops 1% Budesonide Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose Nebuliser soln, 500 mcg per ml, 2 ml Bumetanide Inj 500 mcg per ml, 4 ml Tab 1 mg Bupivacaine hydrochloride Inf 0.125%, 100 ml Inf 0.125%, 100 ml Theatre pack Inf 0.125%, 200 ml Inf 0.125%, 200 ml Theatre pack Inj 0.25%, 20 ml Inj 0.25%, 20 ml Theatre pack Inf 0.25%, 100 ml Inf 0.25%, 100 ml Theatre pack Inj 0.375%, 20 ml Inj 0.375%, 20 ml Theatre pack Inj 0.5%, 4 ml Inj 0.5%, 4 ml Theatre pack Inj 0.5%, 10 ml Inj 0.5%, 10 ml Theatre pack Inj 0.5%, 20 ml Inj 0.5%, 20 ml Theatre pack H H H H H H H H H H H H H H H H 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 18 80 746,518 $127 $122,130 $1.5900 $0.1636 C H C H 1% 1% 4,395,400 17,919,200 1,410 $51,866 $232,950 $5,828 $0.0118 $0.0130 $4.1333 C H C H C 1% 1% 44,180 $86,328 $1.9540 C 11,886 $4,656 $0.3917 * C H H 1% 1% 389,880 $90,725 $0.2327 * C H 1% 96,165 26,760 $22,378 $6,227 $0.2327 $0.2327 * * C C 183,100 3,243,100 $36,803 $129,724 $0.2010 $0.0400 C H C H 1% 1% 741 $2,845 $3.8400 * C H 1%

Chemical Name Line Item Bupivacaine hydrochloride Inj 0.5%, 8% glucose, 4 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

Bupivacaine hydrochloride with Adrenaline Inj 0.25% with 1:400,000 adrenaline, 10 ml Inj 0.25% with 1:400,000 adrenaline, 10 ml Theatre pack Inj 0.5% with 1:200,000 adrenaline, 10 ml Inj 0.5% with 1:200,000 adrenaline, 10 ml Theatre pack Inj 0.5% with 1:200,000 adrenaline, 20 ml Inj 0.5% with 1:200,000 adrenaline, 20 ml Theatre pack Buserelin Acetate Inj 1 mg per ml, 5.5 ml Caffeine Citrate Inj 10 mg per ml, 2.5 ml Oral liq 10 mg per ml Calamine Crm, aqueous, BP Lotn, BP Calcitonin Inj 100 iu per ml, 1 ml Calcitriol Cap 0.25 mcg Cap 0.5 mcg Oral liq 1 mcg per ml Calcium Polystyrene Sulphonate Powder Captopril Oral liq 5 mg per ml Carbachol Eye drops 1.5% Eye drops 3% Carbimazole Tab 5 mg Carboplatin Inj 10 mg per ml, 5 ml Inj 10 mg per ml, 15 ml Inj 10 mg per ml, 45 ml Inj 10 mg per ml, 100 ml Carmustine Inj 100 mg Carvedilol Tab 6.25 mg Tab 12.5 mg $0.7000 $0.9000 C C 19 H PCT 1% H PCT H PCT H PCT H PCT 1% 1% 1% 1% 1,929,703 $208,408 $0.1080 C H 1% 2,445 6,195 $1,112 $2,887 $0.4547 $0.4660 C H C H 1% 1% 183,255 $98,463 $0.5373 C 271,365 $128,030 $0.4718 C H 1% 4,026,344 492,529 10,170 $2,119,065 $433,327 $40,070 $0.5263 $0.8798 $3.9400 C H V C H V C H V 1% 1% 1% 1,725 $34,500 $20.0000 C H 1% 107,535 3,629,263 $3,678 $39,196 $0.0342 $0.0108 * * C H C H 1% 1% H H 1% 1% $97.5000 * C H 1% H H H H H H 1% 1% 1% 1% 1% 1%

Chemical Name Line Item Carvedilol Tab 25 mg Caspofungin Inj 50 mg Inj 70 mg Cefamandole Nafate Inj 500 mg Inj 1 g Inj 2 g Cefpirome Inj 1 g Inj 2 g Cephalexin Monohydrate Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cephradine Cap 250 mg Cap 500 mg Inj 500 mg Inj 1 g Cetomacrogol Cream BP Crm (pack size 100 g or less) Crm (pack size greater than 100 g)

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

$1.1250

H H

1% 1%

$3.6000 $4.3000

C H C H H

1% 1% 1%

H H

1% 1%

75,922 110,548

$5,315 $10,502

$0.0700 $0.0950

C H C H

1% 1%

6,146 18,975 8 8

$3,713 $15,694 $27 $51

$0.6042 $0.8271 $3.3560 $6.3180

C H C H C H C H

1% 1% 1% 1%

5,472,566 5,472,566

$30,646 $30,646

$0.0056 $0.0056

* *

C H C H

1% Volume is aggregated for all

pack sizes of cetomacrogol cream pack sizes of cetomacrogol cream

1% Volume is aggregated for all

Charcoal Tab 300 mg Oral liq 50 g Charcoal with Sorbitol Oral liq 50 g Chloramphenicol Ear drops 0.5% Eye drops 0.5% Eye oint 1% Inj 1 g Chlorhexidine Crm 1% obstetric Mouthwash 0.2% Chlorhexidine Gluconate Handrub 0.5% - 1% with ethanol 70% 2,578,884 $29,399 $0.0114 C 1% Chlorhexidine strengths from

0.5% to 1% would be considered

57,178 135,300

$4,077 $8,930

$0.0713 $0.0660

C H C H

1% 1%

C H

16,160 1,110,390 293,132

$6,044 $113,260 $131,909

$0.3740 $0.1020 $0.4500

C H C H C H H

1% 1% Single dose presentation

would not be a DV Pharmaceutical

1% 1%

H 1,123,800 $15,508 $0.0138 * C

Chloroform BP Chloroform BP $0.0426 * C 1%

Chemical Name Line Item Chlorpheniramine Maleate Oral liq 2 mg per 5 ml Chlorpromazine Hydrochloride Tab 10 mg Tab 25 mg Tab 100 mg Oral liq 100 mg per 5 ml Inj 25 mg per ml, 2 ml Chlorthalidone Tab 25 mg Cholestyramine with Aspartame Sachets 4 g with aspartame Cidofovir Inj 75 mg per ml, 5 ml Cilazapril Tab 0.5 mg Tab 2.5 mg Tab 5 mg Cimetidine Tab 200 mg Tab 400 mg Ciprofloxacin Eye Drops 0.3% Ear drops 10 mg per ml Inj 2 mg per ml, 100 ml Oral liq 250 mg per 5 ml Oral liq 500 mg per 5 ml Clarithromycin Grans for oral liquid 125 mg per 5 ml Inj 500 mg Clobetasol Propionate Crm 0.05% Clobetasone Butyrate Crm 0.05% (pack size 30 g or less) Crm 0.05% (pack size greater than 30 g)

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

7,246,546

$54,349

$0.0075

149,179 1,124,883 399,772 323,824 2,941

$18,439 $146,460 $122,370 $48,574 $7,547

$0.1236 $0.1302 $0.3061 $0.1500 $2.5660

C H C H C H C H C H

1% 1% 1% 1% 1%

133,119

$17,838

$0.1340

C H

150,217

$57,834

$0.3850

8,703,354 12,271,968 11,429,807

$637,956 $1,795,389 $2,453,980

$0.0733 $0.1463 $0.2147

C C C

82,615 245,554

$4,131 $24,555

$0.0500 $0.1000

C H C H

1% 1%

10,360

$25,755

$2.4860

C H H H H H

1% 1% 1% 1% 1%

8,563

$2,828

$0.3303

C H H

1% 1%

1,769,880

$82,653

$0.0467

C H

682,970 672,827

$110,163 $108,527

$0.1613 $0.1613

* *

C H C H

1% Volume is aggregated for all

pack sizes of clobetasone butyrate cream pack sizes of clobetasone butyrate cream

1% Volume is aggregated for all

Clonazepam Inj 1 mg per ml, 1 ml Oral drops 2.5 mg per ml Clostridum botulinum Inj 100 iu Inj 500 u H H 1% 1% 11,968 71,630 $22,404 $52,863 $1.8720 $0.7380 C H C H 1% 1%

Chemical Name Line Item Clotrimazole Pessaries 100 mg with applicator Pessaries 500 mg with applicator Soln 1% Cocaine Soln 4%, 2 ml BP Paste 15% Codeine Phosphate Powder BP Oral liq 25 mg per 5 ml Colestipol Hydrochloride Sachets 5 g Colistin Sulphomethate Inj 150 mg Cortisone Acetate Tab 5 mg Tab 25 mg Co-Trimoxazole Inj 96 mg per ml, 5 ml Crotamiton Crm 10% Lotn 10% Cyclizine Hydrochloride Tab 50 mg Cyclopentolate Hydrochloride Eye drops 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

12,019 3,952 11,340

$3,865 $7,627 $2,472

$0.3216 $1.9300 $0.2180 *

C H C H C

1% 1%

H H

1% 1%

$2.5236

C H H

1% 1%

128,724

$49,559

$0.3850

8,170

$404,742

$49.5400

C H

106,338 39,839

$8,603 $7,442

$0.0809 $0.1868

* *

C H C H

1% 1%

335,100 192,702

$71,376 $29,137

$0.2130 $0.1512

* *

C C

374,931

$47,241

$0.1260

C H

59,265

$34,611

$0.5840

C H

1% Single dose presentation

would not be a DV Pharmaceutical

Cyclophosphamide Inj 200 mg Inj 500 mg Inj 1 g Inj 2 g Tab 50 mg Cyproterone Acetate Tab 50 mg Tab 100 mg Cytarabine Inj 100 mg Inj 500 mg Inj 1 g Inj 2 g Dacarbazine Inj 200 mg H PCT 1% $16.0000 $67.0000 $118.0000 C H PCT C H PCT C H PCT H PCT 1% 1% 1% 1% 1,230,579 $664,513 $0.5400 C H C H 1% 1% 100,022 $51,431 $0.5142 H PCT H PCT C H PCT H PCT C H PCT 1% 1% 1% 1% 1%

Chemical Name Line Item Dalteparin Sodium Inj 2,500 iu per ml, 0.2 ml Inj 5,000 iu per ml, 0.2 ml Inj 7,500 iu per ml, 0.75 ml Inj 10,000 iu per ml, 0.4 ml Inj 10,000 iu per ml, 1 ml Inj 12,500 iu per ml, 0.5 ml Inj 15,000 iu per ml, 0.6 ml Inj 18,000 iu per ml, 0.72 ml Dantrolene Inj 1 mg per ml, 20 ml Dantrolene Sodium Cap 25 mg Cap 50 mg Daunorubicin Inj 20 mg Desferrioxamine Mesylate Inj 500 mg Inj 1 g Desipramine Hydrochloride Tab 25 mg Desmopressin Nasal drops 100 mcg per ml Tab 200 mcg Inj 4 mcg per ml, 1 ml Inj 15 mcg per ml, 1 ml Dexamethasone Eye drops 0.1 % Eye oint 0.1% Dexamethasone Sodium Phosphate Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

H H H H H H H H

1% 1% 1% 1% 1% 1% 1% 1%

138,642 59,695

$45,696 $30,862

$0.3296 $0.5170

* *

C H C H

1% 1%

H PCT

H C H

10% 10%

195,562

$126,411

$0.6464

C H

6,373 1,230 1,290

$99,495 $8,263 $8,666

$15.6120 $6.7180 $6.7180

C H C H C H C H

1% 1% 1% 1%

71,725 6,246

$64,553 $10,458

$0.9000 $1.6743

C H C H

1% 1%

18,308 45,010

$82,752 $293,465

$4.5200 $6.5200

C H C H

1% 1%

Dexamethasone with Framycetin and Gramicidin Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml Ear/Eye oint 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per g 814,000 39,825 $457,875 $35,843 $0.5625 $0.9000 * * C H C H 1% 1%

Dexamethasone with Neomycin and Polymyxin B Sulphate Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g Dexamphetamine Sulphate Tab 5 mg Dextrochlorpheniramine Maleate Oral liq 2 mg per 5 ml 164,426 $2,910 $0.0177 * C 23 568,510 $108,017 $0.1900 C 106,050 9,366 $95,445 $14,424 $0.9000 $1.5400 C H C H 1% 1%

Chemical Name Line Item Dextrochlorpheniramine Maleate Tab 2 mg Tab long-acting 6 mg Dextrose Inj 50%, 10 ml Inj 50%, 50 ml Inj 50%, 90 ml Diazepam Rectal tubes 5 mg Rectal tubes 10 mg Diclofenac Sodium Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg Suppos 25 mg Suppos 50 mg Suppos 100 mg Tab EC 25 mg Tab EC 50 mg Tab 50 mg dispersible Tab long-acting 75 mg Tab long-acting 100 mg Dicloxacillin Cap 250 mg Cap 500 mg Grans for oral liq 125 mg per 5 ml Inj 500 mg Inj 1 g Dicobalt Edetate Inj 15 mg per ml, 20 ml Dicyclomine Hydrochloride Tab 10 mg Didanosine (ddI) Cap 125 mg Cap 200 mg Cap 250 mg Cap 400 mg Diflucortolone Valerate Crm 0.1% Fatty oint 0.1% Oint 0.1% Digoxin Inj 25 mcg per ml, 2 ml Inj 250 mcg per ml, 2 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

121,269 462,152

$6,112 $62,391

$0.0504 $0.1350

* *

C C

2,910

$3,073

$1.0560

C H H H

1% 1% 1%

14,967 17,305

$79,325 $112,067

$5.3000 $6.4760

C H C H

1% 1%

18,900 24,660 5,721 11,867 70,929 183,672 434,748 2,835,341 1,062,339 16,306,696 3,689,008

$52,164 $59,184 $1,058 $2,634 $27,237 $116,815 $15,260 $154,810 $79,675 $875,670 $281,471

$2.7600 $2.4000 $0.1850 $0.2220 $0.3840 $0.6360 $0.0351 $0.0546 $0.0750 $0.0537 $0.0763 *

C H C H C H C H C H C H C H C H C H C H C H

1% Single dose presentation

would not be a DV Pharmaceutical

1% 1% 1% 1% 1% 1% 1% 1% 1% 1%

53,594 126,610 103,721 5 56

$5,515 $20,207 $3,682 $5 $84

$0.1029 $0.1596 $0.0355 $1.0900 $1.5080

* * *

C H C H C H C H C H

1% 1% 1% 1% 1%

682,516

$33,785

$0.0495

3,090 1,630 22,274

$11,850 $10,002 $273,347

$3.8350 $6.1360 $7.6700 $12.2720

C C C C

233,500 288,800 100,300

$41,890 $51,811 $17,994

$0.1794 $0.1794 $0.1794

* * *

C C C

H H

1% 1% 24

Chemical Name Line Item Digoxin Oral liq 50 mcg per ml Tab 62.5 mcg Tab 250 mcg Dinoprostone Gel 1 mg Gel 2 mg Pessary 10 mg Diphemanil Methylsulphate Powder 2% Dipivefrin Hydrochloride Eye drops 0.1% Dipyridamole Tab 25 mg Inj 5 mg per ml, 2 ml Inj 5 mg per ml, 10 ml Disopyramide Phosphate Cap 100 mg Cap 150 mg Disulfiram Tab 200 mg Dithranol Crm 1% Dobutamine Inj 12.5 mg per ml, 20 ml Docetaxel Inj 20 mg Inj 80 mg Docusate Sodium with Bisacodyl Suppos 100 mg with bisacodyl 10 mg Docusate Sodium with Sennosides Tab 50 mg with total sennosides 8 mg Domperidone Tab 10 mg Dopamine Inj 40 mg per ml, 5 ml Dornase Alfa Nebuliser soln 2.5 mg per 2.5 ml ampoule Dorzolamide Hydrochloride Eye drops 2%

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

26,065 10,344,208 2,566,564

$3,524 $268,949 $102,149

$0.1352 $0.0260 $0.0398

C H C H C H

1% 1% 1%

H H H

1% 1% 1%

26,750

$3,643

$0.1362

C H

670

$369

$0.5500

C H

335,494

$705

$0.0021

C H H H

1% 1% 1%

76,305 65,380

$11,446 $17,136

$0.1500 $0.2621

C C

144,132

$35,024

$0.2430

C H

98,850

$54,368

$0.5500

+ +

2,774 $1,637 $0.5900 * C

H PCT H PCT

1% 1%

4,982,810

$194,330

$0.0390

8,748

$429,089

$49.0500

C H

76,460

$149,403

$1.9540

Dorzolamide hydrochloride with timolol maleate Eye drops 2% with timolol maleate 0.5% 363,840 $1,742,794 $4.7900 C

Chemical Name Line Item Dothiepin Hydrochloride Cap 25 mg Tab 75 mg Doxepin Hydrochloride Cap 10 mg Cap 25 mg Cap 50 mg Cap 75 mg Doxorubicin Inj 10 mg Inj 20 mg Inj 50 mg Inj 100 mg Inj 200 mg Doxycycline Hydrochloride Tab 50 mg Inj 5 mg per ml, 2 ml Droperidol Inj 2.5 mg per ml, 1 ml Inj 5 mg per ml, 2 ml Drotrecogin Inj 5 mg Inj 20 mg Econazole Nitrate Crm 1% Foaming soln 1%, 10 ml sachets Pessaries 150 mg with applicators Vaginal crm 1 % with applicator(s) Efavirenz Cap 50 mg Cap 100 mg Cap 200 mg Tab 600 mg Enalapril Tab 5 mg Tab 10 mg Tab 20 mg Enalapril With Hydrochlorothiazide

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

4,798,190 1,690,279

$215,919 $147,899

$0.0450 $0.0875

C C

1,765,919 2,399,878 734,546 391,238

$88,119 $100,555 $51,345 $42,997

$0.0499 $0.0419 $0.0699 $0.1099 *

C C C C

H PCT H PCT H PCT H PCT H PCT

1% 1% 1% 1% 1%

811,894

$78,510

$0.0967

C H H

1% 1%

H H

1% 1%

H H

1% 1%

110,655 59,380 2,282 280

$7,414 $195,758 $2,092 $19

$0.0670 $3.2967 $0.9167 $0.0688

* * * *

C C C C

$5.2777 $5.2777 11,241 $59,327 $5.2777 $15.8330

C C C C

3,526,565 2,875,868 1,995,497

$85,696 $88,289 $81,616

$0.0243 $0.0307 $0.0409

C C C

Tab 20 mg with hydrochlorothiazide 12.5 mg Enoxaparin Sodium Inj 20 mg per 0.2 ml Inj 40 mg per 0.4 ml Inj 60 mg per 0.6 ml Inj 80 mg per 0.8 ml Inj 100 mg per ml

390,522

$43,231

$0.1107

H H H H H

1% 1% 1% 1% 1% 26

Chemical Name Line Item Enoxaparin Sodium Inj 120 mg per 0.8 ml Inj 150 mg per ml Ephedrine Inj 30 mg per ml, 1 ml Tab 30 mg Epirubicin Inj 2 mg per ml, 5 ml Inj 2 mg per ml, 10 ml Inj 2 mg per ml, 25 ml Inj 2 mg per ml, 50 ml Inj 2 mg per ml, 100 ml Eptifibatide Inj 0.75 mg per ml, 100 ml Inj 2 mg per ml, 10 ml Ergometrine Maleate Inj 500 mcg per ml, 1 ml Ergotamine Tartrate with Caffeine Tab 1 mg with caffeine 100 mg Erythromycin Ethyl Succinate Tab 400 mg Erythromycin Lactobionate Inj 1 g Erythromycin Stearate Tab 250 mg Tab 500 mg Esmolol Inj 10 mg per ml, 10 ml Inj 250 mg Ethinyloestradiol Tab 10 mcg Ethinyloestradiol with Gestodene

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

H H

1% 1%

H H

1% 1%

H PCT H PCT H PCT H PCT H PCT

1% 1% 1% 1% 1%

H H

1% 1%

2,329

$5,403

$2.3200

C H

524,621

$162,633

$0.3100

3,667,268

$549,723

$0.1499

C H

256

$1,664

$6.5000

C H

294,450 170,463

$44,020 $50,968

$0.1495 $0.2990

* *

C H C H

1% 1%

H H

1% 1%

358,432

$59,213

$0.1652

Tab 20 mcg with gestodene 75 mcg and 7 inert tab Ethinyloestradiol with Levonorgestrel Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab Tab 30 mcg with levonorgestrel 150 mcg Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab Tab ethinyloestradiol 30 mcg with levonorgestrel 50 mcg (6) and ethinyloestradiol 40 mcg with levonorgestrel 75 mcg (5), and ethinyloestradiol 30 mcg with levonorgestrel 125 mcg (10) and 7 inert tab

29,988

$2,366

$0.0789

9,372,387 584,935 27,000,977 530,957 3,623,857

$738,544 $61,477 $2,127,677 $59,733 $285,560

$0.0788 $0.1051 $0.0788 $0.1125 $0.0788

* *

C C C C

Chemical Name Line Item Ethinyloestradiol with Norethisterone Tab 35 mcg with norethisterone 1 mg

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

65,347 673,620 84,420 53,312

$6,868 $53,081 $8,873 $4,201

$0.1051 $0.0788 $0.1051 $0.0788

* * * *

C C C C

Tab 35 mcg with norethisterone 1 mg and 7 inert tab Tab 35 mcg with norethisterone 500 mcg Tab ethinyloestradiol 35 mcg with norethisterone 500 mcg (7) and tab ethinyloestradiol 35 mcg with norethisterone 1 mg (9) and tab ethinyloestradiol 35 mcg with norethisterone 500 mcg (5) and 7 inert Ethynodiol Diacetate Tab 500 mcg Etidronate Disodium Tab 200 mg Etoposide Cap 50 mg Cap 100 mg Etoposide Phosphate Inj 113.6 mg Inj 568 mg Inj 1,136 mg Fentanyl Inj 50 mcg per ml, 2 ml Inj 50 mcg per ml, 10 ml Inj 50 mcg per ml, 20 ml Transdermal patch 2.5 mg, 25 mcg per hour Transdermal patch 5 mg, 50 mcg per hour Transdermal patch 7.5 mg, 75 mcg per hour Transdermal patch 10 mg, 100 mcg per hour Ferrous Sulphate with Folic Acid Tab long-acting 325 mg with folic acid 350 mcg Fexofenadine Hydrochloride Tab 60 mg Tab 120 mg Tab 180 mg Filgrastim Inj 0.3 mg per ml, 1 ml Inj 0.6 mg per ml, 0.5 ml Flecainide Acetate Tab 50 mg Tab 100 mg Cap long-acting 100 mg Cap long-acting 200 mg Inj 10 mg per ml, 15 ml Flucloxacillin Cap 250 mg

8,348,441

$657,857

$0.0788

2,226,417

$846,038

$0.3800

C H

6,962 424

$118,608 $14,447

$17.0365 $34.0730

C H PCT C H PCT

1% 1%

H PCT H PCT H PCT

1% 1% 1%

H H H H H H H

1% 1% 1% 1% 1% 1% 1%

1,339,145

$80,349

$0.0600

97,701 152,147

$21,201 $72,118

$0.2170 $0.4740

* *

C H C H H

1% 1% 1%

H H

1% 1%

260,780 309,209 561,276 408,740 261

$186,119 $389,758 $801,109 $1,030,434 $2,559

$0.7137 $1.2605 $1.4273 $2.5210 $9.8040

C H C H C H C H C H

1% 1% 1% 1% 1%

1,125,121

$91,810

$0.0816

C H

Chemical Name Line Item Flucloxacillin Cap 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Inj 250 mg Inj 500 mg Inj 1 g Fluconazole Inj 2 mg per ml, 50 ml Oral liq 10 mg per ml Fludrocortisone Acetate Tab 100 mcg Flumazenil Inj 0.1 mg per ml, 5 ml Flumetasone Pivalate Ear drops 0.02% with clioquinol 1% Fluorometholone Eye drops 0.1% Fluorouracil Sodium Crm 5% Inj 25 mg per ml, 100 ml Inj 50 mg per ml, 10 ml Inj 250 mg per 10 ml Inj 500 mg per 10 ml Inj 500 mg per 20 ml Flupenthixol Decanoate Inj 20 mg per ml, 1 ml Inj 20 mg per ml, 2 ml Inj 100 mg per ml, 1 ml Folic Acid Inj 15 mg per ml, 1 ml Tab 0.8 mg Tab 5 mg Framycetin Sulphate Ear/Eye drops 0.5% Ear/Eye oint 0.5% Frusemide Inj 10 mg per ml, 2 ml Inj 20 mg per ml, 2 ml Inf 10 mg per ml, 25 ml Oral liq 10 mg per ml Fusidic Acid Eye drops 1% Inj 500 mg sodium fusidate per 10 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

4,798,296 4,590,778 5,072,788 528 2,848 39,635

$657,367 $117,065 $169,938 $492 $3,104 $59,770

$0.1370 $0.0255 $0.0335 $0.9320 $1.0900 $1.5080

C H C H C H C C C

1% 1% 1%

H H

1% 1%

727,974

$55,472

$0.0762

C H

101,089

$60,118

$0.5947

57,820

$50,766

$0.8780

C H

233,040

$278,366

$1.1945

C H PCT H PCT H PCT

1% 1% 1% 1% 1% 1%

$3.6480 74 568 $426 $3,158 $5.7500 $5.5600

C H PCT C H PCT C H PCT

10,189 10,877 11,426

$26,777 $45,466 $93,396

$2.6280 $4.1800 $8.1740

C H C H C H

1% 1% 1%

H 1,088,795 4,769,637 $17,965 $62,959 $0.0165 $0.0132 C H V C H V

1% 1% 1%

74,216 19,190

$38,310 $14,009

$0.5162 $0.7300

C C

H H 12 100,440 $116 $35,686 $9.6280 $0.3553 C H C H

1% 1% 1% 1%

261,545

$235,391

$0.9000 $12.8700

* *

C H C H

1% 1%

Chemical Name Line Item Fusidic Acid Tab 250 mg Gamma Benzene Hexachloride Crm 1% Ganciclovir Cap 250 mg Inj 500 mg Gatifloxacin Tab 200 mg Tab 400 mg Inj 200 mg per 20 ml Inj 200 mg per 100 ml Inj 400 mg per 200 ml Gentamicin Sulphate Eye drops 0.3% Inj 10 mg per ml, 2 ml Inj 40 mg per ml, 1 ml Inj 40 mg per ml, 2 ml Gestrinone Cap 2.5 mg Glibenclamide Tab 2.5 mg Tab 5 mg Glycerol Liquid BP Suppos 3 g or less Glyceryl Trinitrate Inj 1 mg per ml, 5 ml Inj 1 mg per ml, 50 ml Inj 5 mg per ml, 1 ml Inj 5 mg per ml, 10 ml Tab 600 mcg Glycopyrronium Inj 0.2 mg per ml, 1 ml Haloperidol Inj 5 mg per ml, 1 ml Heparin Sodium Inj 1,000 iu per ml, 1 ml Inj 1,000 iu per ml, 5 ml Inj 5,000 iu per ml, 5 ml Inj 25,000 iu per ml, 0.2 ml Heparinised Saline Inj 10 iu per ml, 5 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

40,811

$117,332

$2.8750

C H

162,400

$10,394

$0.0640

H H

1% 1%

H H H H H

1% 1% 1% 1% 1%

525 70 6,587

$1,197 $224 $3,755

$2.2800 $3.2000 $0.5700

C H C H C H C H

1% Single dose presentation

would not be a DV Pharmaceutical

1% 1% 1%

10,477

$133,412

$12.7338

411,070 1,943,433

$8,139 $40,812

$0.0198 $0.0210

C C

15,000 61,644

$186 $16,027

$0.0124 $0.2600

C H C

H H H H 187,696 $6,194 $0.0330 C H

1% 1% 1% 1% 1%

30,528

$45,242

$1.4820

C H

H 655 15,452 7,519 $875 $42,802 $11,279 $1.3360 $2.7700 $1.5000 * * C H C H C H

1% 1% 1% 1%

24,981

$9,992

$0.4000

C H

1% 30

Chemical Name Line Item Hyaluronidase Inj 1,500 iu per ml Hydralazine Inj 20 mg per ml, 1 ml Hydrocortisone Tab 5 mg Tab 20 mg Oral liq Inj 50 mg per ml, 2 ml Hydrocortisone Acetate Rectal foam 10 %, CFC-free Hydroxychloroquine Sulphate Tab 200 mg Hydroxyurea Cap 500 mg Ibuprofen Tab 400 mg Tab 600 mg Tab long-acting 800 mg Idarubicin Cap 5 mg Cap 10 mg Inj 5 mg Inj 10 mg Ifosfamide Inj 1 g Inj 2 g Imipenem with Cilastatin Inj 500 mg Imipramine Hydrochloride Tab 10 mg Tab 25 mg Indapamide Tab 2.5 mg Indinavir Cap 200 mg Cap 400 mg Indomethacin Cap long-acting 75 mg Suppos 100 mg Infliximab Inj 100 mg Irinotecan Inj 20 mg per ml, 2 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

1,130

$2,070

$1.8320

C H

137

$836

$6.1000

C H

1,906,062 108,611 9,477

$151,532 $15,499 $35,254

$0.0795 $0.1427 $3.7200

C H C H C H C H

1% 1% 1% 1%

244,725

$221,060

$0.9033

C H

1,691,418

$477,995

$0.2826

636,074

$202,017

$0.3176

C H

1,087,638 241,352 2,894,851

$38,720 $12,840 $145,322

$0.0356 $0.0532 $0.0502

* * *

C H C H C H

1% 1% 1%

H PCT H PCT H PCT H PCT

1% 1% 1% 1%

H PCT H PCT

1% 1%

530,032 1,837,460

$52,791 $293,994

$0.0996 $0.1600

C H C H

1% 1%

2,186,771

$73,694

$0.0337

C H

9,930 108,330

$14,337 $312,803

$1.4438 $2.8875

+ C H + C H

C C

1% 1%

700,929 61,113

$87,616 $24,445

$0.1250 $0.4000

H PCT

1% 31

Chemical Name Line Item Irinotecan Inj 20 mg per ml, 5 ml Isoniazid Tab 100 mg Tab 100 mg with rifampicin 150 mg Tab 150 mg with rifampicin 300 mg Isoprenaline Hydrochloride Inj 200 mcg per ml, 1 ml Inj 200 mcg per ml, 5 ml Isosorbide Mononitrate Tab 20 mg Tab long-acting 40 mg Tab long-acting 60 mg Isotretinoin Cap 10 mg Cap 20 mg Cap 40 mg

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

H PCT

323,669 27,750 111,074

$67,970 $24,986 $199,456

$0.2100 $0.9004 $1.7957

C C C

433

$637

$1.4720

C H H

1% 1%

693,452 926,987 12,602,714

$124,821 $458,580 $609,971

$0.1800 $0.4947 $0.0484

C H C H C H

1% 1% 1%

919,941 2,089,869

$367,976 $1,253,921

$0.4000 $0.6000

C H C H C H

1% Information on appropriate use

should be available on a website should be available on a website should be available on a website

1% Information on appropriate use 1% Information on appropriate use

Ketamine Inj 100 mg per ml, 2 ml Ketoprofen Cap 100 mg Cap long-acting 100 mg Cap long-acting 200 mg Ketotifen Oral liq 1 mg per 5 ml Labetalol Inj 5 mg per ml, 20 ml Lamivudine Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 100 mg Tab 150 mg Levobunolol Eye drops 0.25% Eye drops 0.5 % Levocabastine Eye drops 0.5 mg per ml Levodopa with Benserazide Tab dispersible 50 mg with benserazide 12.5 mg Cap 50 mg with benserazide 12.5 mg Cap long-acting 100 mg with benserazide 25 mg 557,056 1,072,722 767,270 $55,706 $85,818 $130,436 $0.1000 $0.0800 $0.1700 C H C H C H 1% 1% 1% 106,288 $231,442 $2.1775 * C 40,785 38,160 $57,099 $53,424 $1.4000 $1.4000 C H C H 1% 1% 660 78,240 203,081 92,718 $248 $32,603 $1,037,155 $474,716 $0.3750 $0.4167 $5.1071 $5.1200 1,043 $12,320 $11.8120 * C H 1% 5,661,484 $138,706 $0.0245 * C 2,356 253,642 278,298 $158 $17,045 $37,403 $0.0672 $0.0672 $0.1344 * * * C C C H 1%

+ C H + C H + C H + C H

1% 1% 1% 1%

Chemical Name Line Item Levodopa with Benserazide Cap 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Levonorgestrel Tab 30 mcg Tab 750 mcg Lignocaine Gel 2% Lignocaine Hydrochloride Inj 0.5%, 5 ml Inj 0.5%, 5 ml Theatre pack Inj 1%, 2 ml Inj 1%, 2 ml Theatre pack Inj 1%, 5 ml Inj 1%, 5 ml Theatre pack Inj 1%, 20 ml Inj 1%, 20 ml Theatre pack Inj 2%, 2 ml Inj 2%, 2 ml Theatre pack Inj 2%, 5 ml Inj 2%, 5 ml Theatre pack Inj 2%, 20 ml Inj 2%, 20 ml Theatre pack Inj twin pack 100 mg per 5 ml Pump spray 10%, 50 ml CFC-free

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

1,028,842 144,663

$128,605 $36,166

$0.1250 $0.2500

C H C H

1% 1%

946,524 147,760

$74,586 $627,980

$0.0788 $4.2500

C C

H H H H H H H H H H H H H H 1,090 $4,633 $4.2500 * C H

1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%

Lignocaine hydrochloride with adrenaline Inj 1% with 1:100,000 adrenaline, 5 ml Inj 1% with 1:100,000 adrenaline, 5 ml Theatre pack Inj 1% with 1:200,000 adrenaline, 20 ml Inj 1% with 1:200,000 adrenaline, 20 ml Theatre pack Inj 2% with 1:200,000 adrenaline, 20 ml Inj 2% with 1:200,000 adrenaline, 20 ml Theatre pack Lignocaine with Chlorhexidine Gel 2% with 0.05% chlorhexidine Lignocaine with Prilocaine Hydrochloride Crm 5%, 5 g Crm 5%, 30 g Patch 5% Linezolid Inf 2 mg per ml, 300 ml Oral liq 20 mg per ml Tab 600 mg H H H 1% 1% 1% H 1% H H H H H H 1% 1% 1% 1% 1% 1%

H H H

1% 1% 1%

Chemical Name Line Item Liposomal Amphotericin Inj 50 mg Lisinopril Tab 5 mg Tab 10 mg Tab 20 mg Lisuride Hydrogen Maleate Tab 200 mcg Lodoxamide trometamol Eye drops 0.1% Lomustine Cap 10 mg Cap 40 mg Lorazepam Tab 0.5 mg Tab 1 mg Tab 2.5 mg Tab sublingal 1 mg Inj 4 mg per ml, 1 ml Magnesium Sulphate Inj 49.3% Paste Maprotiline Hydrochloride Tab 25 mg Tab 75 mg Medroxyprogesterone Acetate Tab 2.5 mg Tab 5 mg Tab 10 mg Tab 100 mg Tab 200 mg Tab 500 mg Mercaptopurine Tab 10 mg Tab 50 mg Meropenem Inj 500 mg Inj 1 g Mesalazine Enema 1 g per 100 ml Metaraminol Tartrate Inj 10 mg per ml, 1 ml Metformin Hydrochloride Tab 500 mg

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

494,577 518,488 510,390

$80,962 $123,400 $171,848

$0.1637 $0.2380 $0.3367

C C C

164,675

$150,958

$0.9167

143,420

$124,919

$0.8710

H H

1% 1%

H 3,420,506 263,431 $55,412 $10,326 $0.0162 $0.0392 C H C H H H

1% 1% 1% 1% 1%

11,416 164,331

$36,851 $6,113

$3.2280 $0.0372 *

C H C H

1% 1%

105,433 30,618

$35,721 $29,047

$0.3388 $0.9487

* *

C C

163,635 582,609 716,772 58,791 2,724

$11,291 $80,109 $180,842 $61,295 $7,087

$0.0690 $0.1375 $0.2523 $1.0426 $2.6018 $3.7800 *

C H C H C H C H C H C H

1% 1% 1% 1% 1% 1%

C H 124,016 $233,448 $1.8824 C H

1% 1%

H H

1% 1%

38,458

$303,818

$7.9000

C H

41,619,757

$978,064

$0.0235

C H

1% 34

Chemical Name Line Item Metformin Hydrochloride Tab 850 mg Methadone Hydrochloride Powder Methotrexate Tab 2.5 mg Tab 10 mg Methotrimeprazine Inj 25 mg per ml, 1 ml Tab 25 mg Tab 100 mg Methoxsalen Cap 10 mg Methyl Hydroxybenzoate Powder Methylphenidate Hydrochloride Tab 5 mg Tab 10 mg Tab 20 mg Tab long-acting 20 mg Methylprednisolone Tab 4 mg Tab 100 mg Methylprednisolone aceponate Crm 0.1% Oint 0.1% Methylprednisolone Sodium Succinate Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Inj 500 mg Inj 1 g Metoclopramide Hydrochloride Inj 5 mg per ml, 2 ml Oral liq 5 mg per 5 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

10,966,489

$361,894

$0.0330

C H

221

$1,845

$8.3500

Pharmacopoeia standard must be specified with Tender Bid

1,519,542 139,471

$293,727 $114,171

$0.1933 $0.8186

C H C H

1% 1%

17,314 441,036 82,633

$127,570 $74,667 $36,325

$7.3680 $0.1693 $0.4396

C H C H C H

1% 1% 1%

25,669

$11,972

$0.4664

$0.6248

C H 2,474,234 2,557,081 $490,641 $1,917,811 $0.1983 $0.7500 C H C H C H

1% 1% 1% 1%

32,997 12,112

$16,027 $100,845

$0.4857 $8.3260

C H C H

1% 1%

319,425 297,375

$105,410 $98,134

$0.3300 $0.3300

C H C H

1% 1%

765 714 163 200

$4,633 $11,784 $6,383 $14,190

$6.0560 $16.5036 $39.1600 $70.9500

C H C H C C

1% 1%

H 784,637 $21,499 $0.0274 * C

Metoclopramide Hydrochloride with Paracetamol Tab 5 mg with paracetamol 500 mg Metolazone Tab 5 mg Metoprolol Tartrate Tab 50 mg Tab 100 mg Tab long-acting 200 mg Inj 1 mg per ml 5 ml 443,852 261,559 110,841 1,635 $66,578 $95,024 $89,859 $7,874 $0.1500 $0.3633 $0.8107 $4.8160 * * C H C H C H C H 1% 1% 1% 1% H 1% 988,244 $53,563 $0.0542 C

Chemical Name Line Item Metronidazole Oral liq benzoate 200 mg per 5 ml Suppos 500 mg Suppos 1 g Metyrapone Cap 250 mg Mianserin Hydrochloride Tab 30 mg Miconazole Nitrate Lotn 2% Powder 2% Tincture 2% Vaginal crm 2% with applicator Midodrine Tab 2.5 mg Tab 5 mg Mifepristone Tab 200 mg Milrinone Inj 1 mg per ml, 10 ml Minoxidil Tab 2.5 mg Tab 5 mg Tab 10 mg Misoprostol Tab 200 mcg Mitozantrone Inj 2 mg per ml, 5 ml Inj 2 mg per ml, 10 ml Moclobemide Tab 150 mg Tab 300 mg Mometasone Furoate Oint 0.1% (pack size 30 g or less) Oint 0.1% (pack size greater than 30 g) Crm 0.1% (pack size 30 g or less) Crm 0.1% (pack size greater than 30 g)

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

216,594 3,164 2,286

$38,575 $7,040 $6,922

$0.1781 $2.2250 $3.0280

C H C H C H

1% 1% 1%

8,981

$38,992

$4.3416

62,477

$60,915

$0.9750

17,430 31,110 438,080

$2,533 $4,520 $30,140

$0.1453 $0.1453 $0.0688

* * *

C H H C H C H

1% 1% 1% 1%

59,189 70,423

$31,370 $55,634

$0.5300 $0.7900

C C

H H H

1% 1% 1%

117,737

$51,710

$0.4392

H PCT H PCT

1% 1%

1,786,504 406,847

$164,358 $106,228

$0.0920 $0.2611

C C

1,772,685 1,757,835 2,278,695 2,239,380

$446,717 $442,974 $574,231 $564,324

$0.2520 $0.2520 $0.2520 $0.2520

+ C + C + C + C

Volume is aggregated for all pack sizes of mometasone furoate ointment Volume is aggregated for all pack sizes of mometasone furoate ointment Volume is aggregated for all pack sizes of mometasone furoate cream Volume is aggregated for all pack sizes of mometasone furoate cream

Morphine Hydrochloride Oral liq 1 mg per ml Oral liq 2 mg per ml 5,204,748 925,833 $199,862 $37,774 $0.0384 $0.0408 C H C H 1% 1%

Chemical Name Line Item Morphine Hydrochloride Oral liq 5 mg per ml Oral liq 10 mg per ml Morphine Sulphate Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Tab immediate release 10 mg Tab immediate release 20 mg Cap long-acting 10 mg Cap long-acting 30 mg Cap long-acting 60 mg Cap long-acting 100 mg Cap long-acting 200 mg Tab long-acting 10 mg Tab long-acting 30 mg Tab long-acting 60 mg Tab long-acting 100 mg Tab long-acting 200 mg Suppos 5 mg Suppos 10 mg Suppos 20 mg Suppos 30 mg Morphine Tartrate Inj 80 mg per ml, 1.5 ml Inj 80 mg per ml, 5 ml Moxifloxacin Inj 1.6 mg per ml, 250 ml Tab 400 mg Mucilaginous Laxatives Dry-original flavour, regular texture only Sugar Free Mucilaginous Laxatives with Stimulants Dry Mupirocin Oint 2% Nafarelin Acetate Nasal soln 2 mg per ml Naloxone Hydrochloride Inj 20 mcg per ml, 2 ml Inj 400 mcg per ml, 1 ml Naltrexone hydrochloride Tab 50 mg Nandrolone Decanoate Inj 50 mg per ml, 1 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

889,721 597,172

$40,838 $35,711

$0.0459 $0.0598

C H C H

1% 1%

13,327 13,397 905,877 464,422 2,975,554

$13,780 $12,593 $239,152 $236,855 $535,600

$1.0340 $0.9400 $0.2640 $0.5100 $0.1800 $0.3600 $0.7200

C H C H C H C H C H C H C H C H C H * * * C H C H C H C H C H C H C H C H C H

1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%

355,079 543,029 269,074 168,223 199,609 389 244 5,623 1,392

$301,817 $97,745 $96,867 $121,121 $169,668 $575 $389 $9,517 $3,641

$0.8500 $1.7000 $0.1800 $0.3600 $0.7200 $0.8500 $1.4783 $1.5950 $1.6925 $2.6158

29,919 2,529

$120,873 $34,076

$4.0400 $13.4740

C H C H

1% 1%

H H

1% 1%

15,815,856 702,625

$278,359 $12,366

$0.0176 $0.0176

* *

C H C H

1% 1%

8,647,900

$152,203

$0.0176

C H

1,482,870

$652,463

$0.4400

C H

200

$5,540

$27.7000

245 8,619

$1,468 $46,543

$5.9900 $5.4000

C C H

Min-I-Jet would not be DV Pharmaceutical

1% Min-I-Jet would not be DV

Pharmaceutical

$6.0000

C H

699

$14,784

$21.1500

C H

1% 37

Chemical Name Line Item Naproxen Oral liq 125 mg per 5 ml Tab 250 mg Tab 500 mg Naproxen Sodium Tab 275 mg Tab 550 mg Nedocromil Aerosol Inhaler, 2 mg per dose CFC-free Nefopam Hydrochloride Inj 20 mg per ml, 1 ml Tab 30 mg Nelfinavir Powder 50 mg per g Tab 250 mg Neostigmine methylsulphate Inj 2.5 mg per ml, 1 ml Nevirapine Oral suspension 50 mg per 5 ml Tab 200 mg Nicotinic Acid Tab 25 mg Tab 50 mg Tab 100 mg Tab 500 mg Nifedipine Tab long-acting 10 mg Tab long-acting 20 mg Nimodipine Inj 0.2 mg per ml, 50 ml Nitrazepam Tab 5 mg Nitrofurantoin Tab 50 mg Tab 100 mg Oral liq 25 mg per 5 ml Noradrenaline Inj 1 mg per ml, 2 ml Norethisterone Tab 350 mcg Norethisterone with Mestranol Tab 1 mg with mestranol 50 mcg

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

C 1,105,811 2,595,827 $58,608 $275,158 $0.0530 $0.1060 C C

1,345,244 2,809,823

$86,096 $359,657

$0.0640 $0.1280

C C

1,079,792

$223,625

$0.2071

33 1,176,071

$60 $305,778

$1.8200 $0.2600

C H C H

1% 1%

16,560 151,044

$6,376 $335,650

$0.3850 $2.2222

+ C + C H

H 1%

+ C H

89,258 $475,745 $5.3300

1% 1%

+ C H

C C C C V V V

229,542 231,837 330,263 636,998

$6,083 $11,105 $23,019 $102,875

$0.0265 $0.0479 $0.0697 $0.1615

262,176 759,123

$74,982 $52,759

$0.2860 $0.0695

C H C H

1% 1%

895,655

$17,913

$0.0200

1,421,442 202,309

$224,588 $56,040

$0.1580 $0.2770

C H C H C H

1% 1% 1%

2,158,005

$183,646

$0.0851

13,851 80,010

$1,456 $6,305

$0.1051 $0.0788

* *

C C

Tab 1 mg with mestranol 50 mcg and 7 inert tab

Chemical Name Line Item Nystatin Pastilles 100,000 u Pessary 100,000 iu

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

296,240 87,375

$66,654 $5,129

$0.2250 $0.0587

* *

C H H C

1% 1%

Vaginal crm 100,000 u per 5 g with applicator(s) Oestradiol Tab 2 mg Oestradiol valerate Tab 1 mg Tab 2 mg Oestradiol with levonorgestrel Tab 2 mg with 75 mcg levonorgestrel tab (12) and 2 mg oestradiol tab (16) Oestradiol with norethisterone Tab 1 mg with 0.5 mg norethisterone acetate Tab 2 mg with 1 mg norethisterone acetate Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6) Oestriol Crm 1 mg per g with applicator Pessaries 500 mcg Tab 2 mg Oestrogens Conjugated, equine tab 1.25 mg Conjugated, equine tab 300 mcg Conjugated, equine tab 625 mcg Oestrogens with medroxyprogesterone Tab 625 mcg conjugated equine (14) and 5 mg medroxyprogesterone acetate tab (14) Tab 625 mcg conjugated equine (28) and 10 mg medroxyprogesterone acetate tab (14) Tab 625 mcg conjugated equine (28) and 2.5 mg medroxyprogesterone acetate tab (28) Tab 625 mcg conjugated equine (28) and 5 mg medroxyprogesterone acetate tab (28) Tab 625 mcg conjugated equine and 5 mg medroxyprogesterone acetate tab (28) Oily Phenol Inj 5%, 5 ml Olsalazine Cap 250 mg Tab 500 mg Ornidazole Tab 500 mg Orphenadrine Citrate Inj 30 mg per ml, 2 ml Tab 100 mg

671,888

$129,607

$0.1929

191,471 255,065

$28,165 $49,202

$0.1471 $0.1929

C C

99,354

$19,165

$0.1929

987,196 614,320 386,120

$190,430 $118,502 $74,483

$0.1929 $0.1929 $0.1929

* * *

C C C

1,181,070 226,677 199,565

$551,205 $109,553 $46,559

$0.4667 $0.4833 $0.2333

C H C H C H

1% 1% 1%

459,940 1,711,771 1,393,001

$115,813 $184,015 $204,910

$0.2518 $0.1075 $0.1471

C C C

191,492 13,440 419,468 1,120 520,800

$36,939 $1,728 $80,915 $108 $100,462

$0.1929 $0.1286 $0.1929 $0.0964 $0.1929

* * * * *

C C C C C

580

$8,318

$14.3420

C H

233,195 174,230

$73,480 $104,294

$0.3151 $0.5986

C C

130,138

$161,111

$1.2380

90 1,060,568

$288 $196,629

$3.2000 $0.1854

C H C H

1% 1%

Chemical Name Line Item Orphenadrine Hydrochloride Tab 50 mg Oxazepam Tab 10 mg Tab 15 mg Oxypentifylline Tab 400 mg Oxytocin Inj 5 iu per ml, 1 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

473,370

$60,449

$0.1277

C H

1,111,190 485,729

$22,002 $11,900

$0.0198 $0.0245

* *

C C

51,991

$38,411

$0.7388

C H

1,150 2,103 3,263

$1,136 $3,533 $4,033

$0.9880 $1.6800 $1.2360

C H C H C H

1% 1% 1%

Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml Inj 10 iu per ml, 1 ml Pancuronium bromide Inj 2 mg per ml, 2 ml Pantoprazole Inj 40 mg Tab 20 mg Tab 40 mg Paracetamol Suppos 25 mg Suppos 50 mg Paraffin White soft or yellow soft (pack size 30 g or less) White soft or yellow soft (pack size 100 g or more) Liquid BP Paraffin Liquid with Soft White Paraffin Eye oint with soft white paraffin Paraffin Liquid with Wool Fat Liquid Eye oint 3% with wool fat liq 3% Penicillamine Tab 125 mg Tab 250 mg Pentastarch Plasma Expander Inj 6%, 500 ml Perhexiline Maleate Tab 100 mg Pericyazine Tab 2.5 mg Tab 10 mg Phenindione Tab 10 mg Tab 25 mg Tab 50 mg

H 4,936,086 8,309,706 $899,848 $1,930,345 $0.1823 $0.2323 * * C H C H

1% 1% 1%

H H

1% 1%

H * C H H

1% 1% 1% Sterile 5 g preparation would

not be a DV Pharmaceutical

76,550

$79,390

$1.0371

25,844

$26,803

$1.0371

40,863 78,014

$23,006 $70,197

$0.5630 $0.8998

* *

C C

324,141

$169,915

$0.5242

C H

197,989 92,220

$24,729 $40,992

$0.1249 $0.4445

C H C H

1% 1%

H H H

1% 1% 1% 40

Chemical Name Line Item Phenoxybenzamine Cap 10 mg Phenoxymethylpenicillin (Penicillin V) Cap 250 mg Cap 500 mg Phenylephrine Inj 1%, 1 ml Phenylephrine Hydrochloride Eye drops 0.12%

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

78,615

$20,479

$0.2605

C H

494,793 1,419,952

$42,453 $231,452

$0.0858 $0.1630

C C

31,470

$6,820

$0.2167

C H

Phenylephrine Hydrochloride with Zinc Sulphate Eye drops 0.12% with zinc sulphate 0.25% Physostigmine Salicylate Inj 500 mcg per ml, 2 ml Phytomenadione Inj 2 mg per 0.2 ml Inj 10 mg per ml, 1 ml Tab 10 mg Piperacillin with Tazobactam Inj 2.25 g Inj 4.5 g Pipothiazine Palmitate Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml Pizotifen Tab 500 mcg Podophyllotoxin Soln 0.5% Polyethylene glycol with sodium sulphate Powder, sachets Polyvinyl Alcohol Eye drops 1.4% Eye drops 3% Polyvinyl Alcohol with Povidone Eye drops 1.4% with povidone 0.6% Potassium Bicarbonate Tab 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg, effervescent Potassium Chloride Tab 548 mg (14 m eq) with chloride 285 mg (8 m eq) effervescent Tab long-acting 600 mg Povidone Iodine Alcohol skin preparation 10% Antiseptic Soln 10% 530,000 1,433,317 $8,639 $18,346 $0.0163 $0.0128 * * C C 41 362,423 12,979,763 $31,784 $319,302 $0.0877 $0.0246 * C C H 1% 51,902 $38,927 $0.7500 C 326,925 $78,887 $0.2413 C 240,675 58,350 $58,075 $15,095 $0.2413 $0.2587 C H C H 1% 1% H 1% 18,802 $171,905 $9.1429 C H 1% 1,731,826 $365,415 $0.2110 * C 3,641 1,509 $64,985 $53,316 $17.8480 $35.3320 C H C H 1% 1% H H 1% 1% 7,044 3,215 28,983 $11,270 $5,922 $16,230 $1.6000 $1.8420 $0.5600 C H C H C H 1% 1% 1% $11.0400 C H 1% 19,470 $5,855 $0.3007 C H 1%

Chemical Name Line Item Povidone Iodine Oint 10% Prednisolone Acetate Eye drops 0.12% Eye drops 1% Pregnancy Tests - HCG Urine Urine diagnostic test Prilocaine hydrochloride Inj 0.5%, 50 ml Inj 1%, 5 ml Inj 2%, 5 ml Probenecid Tab 500 mg Prochlorperazine Inj 12.5 mg per ml, 1 ml Suppos 5 mg Suppos 25 mg Tab 3 mg buccal Procyclidine Hydrochloride Tab 5 mg Promethazine Hydrochloride Inj 25 mg per ml, 1 ml Oral liq 5 mg per 5 ml Promethazine Theoclate Tab 25 mg Propafenone Hydrochloride Tab 150 mg Protamine Sulphate Inj 10 mg per ml, 5 ml Pyrazinamide Tab 500 mg Pyridostigmine Bromide Tab 60 mg Pyridoxine Hydrochloride Tab 25 mg Tab 50 mg Tab 100 mg Quinine Sulphate Tab 200 mg Tab 300 mg Rasburicase Inj 1.5 mg

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

198,150

$21,598

$0.1090

34,820 137,530

$31,338 $123,777

$0.9000 $0.9000

* *

C H C H

1% 1%

380,600

$449,108

$1.1800

H H H

1% 1% 1%

229,851

$126,418

$0.5500

35,011 7,744 15,359 246,206

$52,201 $14,737 $38,520 $29,397

$1.4910 $1.9030 $2.5080 $0.1194

* * * *

C H C H C H C H

1% PSO Maximum pack size is 5

injections

1% 1% 1%

723,276

$53,522

$0.0740

C H

20,819 5,761,734

$26,398 $203,389

$1.2680 $0.0353

* *

C H C H

1% 1%

4,336

$520

$0.1200

90,917

$74,370

$0.8180

5,726

$12,826

$2.2400

C H

107,360

$63,342

$0.5900

315,126

$90,126

$0.2860

456,762 689,398 324,402

$15,530 $17,373 $17,453

$0.0340 $0.0252 $0.0538

* * *

C H V C H V C H V

1% 1% 1%

1,494,528 3,411,548

$98,639 $238,808

$0.0660 $0.0700

C H C H

1% 1%

Chemical Name Line Item Rifabutin Cap 150 mg Rifampicin Inj 600 mg Oral liq 100 mg per 5 ml Cap 150 mg Cap 300 mg Tab 600 mg Ritonavir Cap 100 mg Oral liq 80 mg per ml Rocuronium Inj 10 mg per ml, 5 ml Inj 10 mg per ml, 10 ml Ropivacaine hydrochloride Inj 2 mg per ml, 10 ml Inj 2 mg per ml, 10 ml Theatre pack Inj 2 mg per ml, 20 ml Inj 2 mg per ml, 20 ml Theatre pack Inj 2 mg per ml, 100 ml Inj 2 mg per ml, 100 ml Theatre pack Inj 2 mg per ml, 200 ml Inj 2 mg per ml, 200 ml Theatre pack Inj 7.5 mg per ml, 10 ml Inj 7.5 mg per ml, 10 ml Theatre pack Inj 7.5 mg per ml, 20 ml Inj 7.5 mg per ml, 20 ml Theatre pack Inj 10 mg per ml, 10 ml Inj 10 mg per ml, 10 ml Theatre pack Inj 10 mg per ml, 20 ml Inj 10 mg per ml, 20 ml Theatre pack Ropivacaine hydrochloride with Fentanyl Inj 2 mg with 2 mcg fentanyl per ml, 100 ml Inj 2 mg with 2 mcg fentanyl per ml, 100 ml Theatre pack Inj 2 mg with 2 mcg fentanyl per ml, 200 ml Inj 2 mg with 2 mcg fentanyl per ml, 200 ml Theatre pack Roxithromycin Tab 150 mg Tab 300 mg Salbutamol Inf 1 mg per ml, 5 ml Inj 500 mcg per ml, 1 ml Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

8,318

$59,110

$7.1063

H 103,679 53,925 85,679 15,335 $21,876 $31,632 $104,837 $58,477 $0.2110 $0.5866 $1.2236 $3.8133 C H C H C H C H

1% 1% 1% 1% 1%

88,705

$128,072

$1.4438 $1.1553

+ C H + C H

H H

1% 1%

H H H H H H H H H H H H H H H H

1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%

H H H H

1% 1% 1% 1%

1,097,398 433,276

$328,122 $259,099

$0.2990 $0.5980

C H C H

1% 1%

H 2,771 411,382 1,061,712 $7,149 $99,349 $270,737 $2.5800 $0.2415 $0.2550 C H C H C H

1% 1% 1% 1% 43

Chemical Name Line Item Salbutamol with Ipratropium Bromide

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml vial Saquinavir Cap 200 mg Selegiline Hydrochloride Tab 5 mg Sertraline Tab 50 mg Tab 100 mg Sodium Acid Phosphate Enema 16% with sodium phosphate 8% Sodium Aurothiomalate Inj 10 mg per 0.5 ml Inj 20 mg per 0.5 ml Inj 50 mg per 0.5 ml Sodium Bicarbonate Inj 8.4%, 10 ml Sodium Calcium Edetate Inj 200 mg per ml, 5 ml Sodium Chloride Inj 0.9%, 5 ml Inj 0.9%, 10 ml Inj 0.9%, 20 ml Inj 20%, 10 ml Inj 4 mmol per ml, 20 ml

1,980,899

$1,035,020

$0.5225

58,446

$87,990

$1.5055

+ C

198,457

$33,559

$0.1691

H H

1% 1%

30,361

$75,903

$2.5000

C H

126 213 3,652

$969 $2,411 $79,332

$7.6870 $11.3170 $21.7230

C H C H C H

1% Small pack sizes preferred 1% Small pack sizes preferred 1% Small pack sizes preferred

811

$1,632

$2.0120

C H

$8.8850

C H

103,337 367,619 77,586 1,345

$33,068 $158,444 $4,032

$0.3200 $0.4310 * $2.9976

C H C H C H C H H

1% 1% 1% 1% 1%

Sodium Citrate with Sodium Lauryl Sulphoacetate Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Sodium Citro-Tartrate Grans effervescent 4 g sachets Sodium Cromoglycate Cap 100 mg Nasal spray, 4% Sodium Hyaluronate Inj 3% with 4% chondroitin sulphate, 0.35 ml Inj 3% with 4% chondroitin sulphate, 0.5 ml Ophthalmic inj 14 mg per ml Ophthalmic soln 10 mg per ml Sodium Hypochlorite Soln Sodium Polystyrene Sulphonate Powder 175,889 $34,826 $0.1980 C H 1% 68,750 $76 $0.0011 C H H H H 1% 1% 1% 1% 94,255 82,896 $84,085 $60,589 $0.8921 $0.7309 * C C H 1% 329,446 $200,402 $0.6083 C H 1%

Chemical Name Line Item Sodium Tetradecyl Sulphate Inj 0.5% 2 ml Inj 1% 2 ml Inj 3% 2 ml Sotalol Inj 10 mg per ml, 4 ml Spironolactone Tab 25 mg Tab 100 mg Sulindac Tab 100 mg Tab 200 mg Sulphacetamide Sodium Eye drops 10% Sulphasalazine Enema 3 g per 100 ml Tab 500 mg Tab EC 500 mg Suxamethonium Inj 100 mg per 2 ml Teicoplanin Inj 400 mg Tenoxicam Inj 10 mg per ml, 2 ml Inj 20 mg per ml, 2 ml Suppos 20 mg Tab 20 mg Testosterone Cypionate Inj long-acting 100 mg per ml, 10 ml Testosterone Enanthate Inj long-acting 250 mg - prefilled syringe Testosterone Undecanoate Cap 40 mg Tetrabenazine Tab 25 mg Tetracosactrin Inj 250 mcg Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Theophylline Tab long-acting 250 mg Tab long-acting 350 mg Thiamine Hydrochloride Inj 100 mg per ml, 2 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

15 36 219

$70 $180 $1,248

$4.6400 $5.0000 $5.7000

* * *

C H C H C H

1% 1% 1%

664

$5,490

$8.2680

C H

4,995,982 1,209,484

$424,658 $262,458

$0.0850 $0.2170

C H C H

1% 1%

177,562 232,155

$9,446 $15,601

$0.0532 $0.0672

* *

C C

43,274

$12,679

$0.2930

$5.3429 302,368 6,036,554 $26,790 $600,033 $0.0886 $0.0994

C C C

64,073 13,941 2,297,020 $128,146 $7,389 $545,542 $2.0000 $0.5300 $0.2375

C H C H C H C H

1% 1% 1% 1%

410

$25,178

$61.4100

C H

4,012

$60,180

$15.0000

C H

727,302

$735,884

$1.0118

C H

105,494

$228,880

$2.1696

310 408

$5,493 $10,967

$17.7180 $26.8800

C H C H H

1% 1% 1%

1,442,342 379,436

$310,248 $111,099

$0.2151 $0.2928

C C

C H

1% 45

Chemical Name Line Item Thiamine Hydrochloride Tab 10 mg Tab 25 mg Tab 50 mg Tab 100 mg Thioridazine Hydrochloride Tab 10 mg Tab 25 mg Tab 50 mg Tab 100 mg Tab long-acting 200 mg Thrombin Inj 5,000 iu Thyroxine Tab 50 mcg Tab 100 mcg Tiaprofenic Acid Tab 300 mg Cap long-acting 300 mg Timolol Tab 10 mg Timolol Maleate Eye drops 0.25%, gel forming Eye drops 0.5%, gel forming Timolol Maleate with Pilocarpine Eye drops 0.5% with pilocarpine 2% Eye drops 0.5% with pilocarpine 4% Tinazaparin Sodium Inj 3,500 anti-Xa IU per 0.35 ml Inj 4,500 anti-Xa IU per 0.45 ml Inj 10,000 anti-Xa IU per 0.5 ml Inj 14,000 anti-Xa IU per 0.7 ml Inj 18,000 anti-Xa IU per 0.9 ml Inj 20,000 anti-Xa IU per 2 ml Tinidazole Tab 500 mg Tirofiban Inj 0.25 mg per ml, 50 ml Tobramycin Eye drops 0.3% Eye oint 0.3% Inj 40 mg per ml, 1 ml Tolbutamide Tab 500 mg

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

52,711 215,084 1,246,563

$1,771 $8,388 $52,106

$0.0336 $0.0390 $0.0418

* *

C H V C H V C H V C H V

1% 1% 1% 1%

361,048 467,045 235,385 124,190 14,400

$27,584 $40,726 $27,870 $23,646 $6,480

$0.0764 $0.0872 $0.1184 $0.1904 $0.4500

C H C H C H C H C

1% 1% 1% 1%

22,115,465 9,261,109

$751,926 $351,922

$0.0340 $0.0380

C C

95,525 394,571

$6,419 $26,555

$0.0672 $0.0673

* *

C C

274,182

$30,462

$0.1111

24,423 52,403

$78,154 $178,170

$3.2000 $3.4000

C C

25,360 9,305

$70,754 $25,961

$2.7900 $2.7900

C C

H H H H H H

1% 1% 1% 1% 1% 1%

30,179

$31,437

$1.0417

C H

5,255 1,571

$12,065 $4,691

$2.2960 $2.9857

C H C H C H

1% 1% 1%

170,976

$20,517

$0.1200

C H

1% 46

Chemical Name Line Item Tolcapone Tab 100 mg Tranexamic Acid Inj 100 mg per ml, 5 ml Tranylcypromine Sulphate Tab 10 mg Triamcinolone Acetonide Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 5 ml Inj 40 mg per ml, 1 ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

202,757

$261,050

$1.2875

251,009

$115,163

$0.4588

4,206 126 52,950

$9,346 $1,299 $297,473

$2.2220 $10.3100 $5.6180

C H C H C H

1% 1% 1%

Triamcinolone Acetonide with Gramicidin, Neomycin and Nystatin Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Trifluoperazine Hydrochloride Cap long acting 15 mg Oral liq 1 mg per ml Tab 1 mg Tab 2 mg Tab 5 mg Trimeprazine Tartrate Oral liq 30 mg per 5 ml Trimethoprim Tab 100 mg Oral liq 50 mg per 5 ml Tropicamide Eye drops 0.5% Eye drops 1% 945 2,820 $450 $1,628 $0.4767 $0.5773 C H C H 1% Single dose presentation

would not be a DV Pharmaceutical would not be a DV Pharmaceutical

495,090 111,967

$115,207 $38,371

$0.2327 $0.3427

C C H

1% 1%

C H 16,446 280,600 299,013 521,585 $1,230 $27,583 $40,755 $82,358 $0.0748 $0.0983 $0.1363 $0.1579 * * * C H C H C H C H

1% 1% 1% 1% 1%

372,665

$10,397

$0.0279

C H C H

1% 1%

1% Single dose presentation

Tropisetron Inj 1 mg per ml, 2 ml Cap 5 mg Tyloxapol Eye drops 0.25% Urokinase Inj 10,000 iu Inj 100,000 iu Inj 500,000 iu Vancomycin Hydrochloride Inj 500 mg Vasopressin Inj 20 iu per ml, 1 ml H 1% 47 1,720 $11,008 $6.4000 C H 1% H H H 1% 1% 1% 6,180 $3,555 $0.5753 C H H 1% 1%

Chemical Name Line Item Vecuronium Inj 4 mg Inj 10 mg Verapamil Hydrochloride Inj 2.5 mg per ml, 2 ml Vincristine Sulphate Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Inj 1 mg per ml, 5 ml Vinorelbine Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 5 ml Vitamin A with Vitamins D and C

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Units Cost Unit Subsidy DV Limit Comments

H H

1% 1%

996

$1,502

$1.5080

C H

$26.6000 $53.2400

C H PCT C H PCT C H PCT

1% 1% 1%

H PCT H PCT

1% 1%

Soln 1,000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops Vitamin B Complex Tab Vitamins Tab (BPC cap strength ) Water for Injection Purified for inj 5 ml Purified for inj 10 ml Purified for inj 20 ml Zidovudine (AZT) Cap 100 mg Inj 200 mg per 20 ml Oral liq 10 mg per ml Zidovudine (AZT) with Lamivudine Tab 300 mg with lamivudine 150 mg Zinc and Castor Oil Oint (pack size 30 g or less) Oint (pack size 100 g or more)

167,120

$73,199

$0.4380

1,077,436

$26,074

$0.0242

23,772,766

$370,855

$0.0156

H H 19,904 $13,933 $0.7000 C H

1% 1% 1%

34,719 171,400

$100,685 $49,706

$2.9000 $0.2900

+ C H +

1% 1% 1%

+ C H + C H

H H

296,484

$3,296,902

$11.1200

1% 1%

Schedule 3

Schedule 3: Tender Process

1.1

General Sole Supply Period and Hospital Supply Status Period

(a) Hospital Tender Bids are to be submitted on the basis that if your Hospital Tender Bid is accepted, you will have Hospital Supply Status for the particular Tender Item for the Hospital Supply Status Period. Community Tender Bids are to be submitted on the basis that if your Community Tender Bid is accepted, you will have Sole Supply Status for the particular Tender Item for the Sole Supply Period. Combined Community/Hospital Tender Bids are to be submitted on the basis that if your Combined Community/Hospital Tender Bid is accepted, you will have Hospital Supply Status for the particular Tender Item for the Hospital Supply Status Period and Sole Supply Status for the particular Tender Item for the Sole Supply Period.

(b)

(c)

1.2

Transition Periods

(a) In relation to hospital supply: (i) there will be two Transition Periods (the First Transition Period and the Final Transition Period) during which the successful tenderer’s brand is to be available for supply and purchased by DHB Hospitals; the First Transition Period is intended to allow for an orderly transition to the arrangements that will apply during the Hospital Supply Status Period; the Final Transition Period is intended to allow for an orderly transition to any new arrangements following the end of the Hospital Supply Status Period; DHB Hospitals may purchase DV Pharmaceuticals at any time within the First Transition Period and Final Transition Period without any requirement to comply with the DV Limit.

(ii) (iii) (iv)

(b)

Subject to paragraph (d) below, in relation to community supply: (i) there will be three Transition Periods (the First Transition Period, the Second Transition Period and the Final Transition Period) during which the successful tenderer’s brand is to be available for supply and subsidised, but may not be the sole subsidised brand of that Tender Item; the First Transition Period and Second Transition Period are intended to allow for an orderly transition to the arrangements that will apply during the Sole Supply Period; the Final Transition Period is intended to allow for an orderly transition to any new arrangements following the end of the Sole Supply Period.

(ii)

(iii) (c)

In relation to community and/or hospital supply, PHARMAC may, in its sole discretion: (i) determine a different commencement date for the First Transition Period and/or Second Transition Period, as applicable, including where it considers that a

R33-4-0 #94186

Schedule 3 different commencement date is necessary to ensure appropriate stock management or appropriate supply of the Tender Item; and/or (ii) extend the period of the First Transition Period and/or Second Transition Period, as applicable, by determining a different end date, and may do so before or after the commencement date of the relevant First Transition Period or Second Transition Period. For the avoidance of doubt, in the event that PHARMAC extends the Second Transition Period under this clause 1.2(c)(ii): (A) the delisting of all other brands of that form and strength of the Chemical Entity is to be deferred until the actual commencement date of the Sole Supply Period, notwithstanding any date previously notified to suppliers by PHARMAC as being the intended date of delisting; all other brands of that form and strength of the Chemical Entity are to remain listed in accordance with the terms of any existing contract between PHARMAC and the particular pharmaceutical supplier in respect of the relevant brand(s) until such time as that supplier’s brand of that form and strength of the Chemical Entity is actually delisted.

(B)

(d)

In relation to community supply, if the successful tenderer’s brand is the only brand of the Tender Item listed on the Pharmaceutical Schedule as at the time PHARMAC notifies the market that a Tender has been accepted for a Tender Item, then the First Transition Period and clause 2.1(a) of Schedule Six will not apply and, subject to paragraph (c) above, the Second Transition Period is to begin on the first day of the second month following the date of such notification. For the avoidance of doubt, any notification by PHARMAC of the delisting of all other brands of that form and strength of the Chemical Entity on the first day of the Sole Supply Period operates solely as advance notice of the intended delisting of those pharmaceuticals and does not constitute a notice of termination of any existing contract for the supply of those other brands.

(e)

1.3

Contract

If PHARMAC accepts your: (a) Community Tender Bid, then a contract on the terms and conditions set out in: (i) (ii) (iii) your Tender Bid (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule); and Schedule Six; and if PHARMAC accepts a Foreign Exchange Bid from you, Schedule Seven,

R33-4-0 #94186

your Tender Bid (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule); and Schedule Five; and if PHARMAC accepts a Foreign Exchange Bid from you, Schedule Seven,

Schedule 3 will be deemed to have been entered into between you and PHARMAC for Hospital Supply Status for the relevant Pharmaceutical and, where applicable, its listing on the Pharmaceutical Schedule; (c) Combined Community/Hospital Tender Bid, then: (i) a contract on the terms and conditions set out in: (A) your Tender Bid, to the extent applicable (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule); and for the Hospital Tender Bid element of that Combined Community/Hospital Tender Bid, Schedule Five; and if PHARMAC accepts a Foreign Exchange Bid from you, Schedule Seven,

(B) (C)

will be deemed to have been entered into between you and PHARMAC for Hospital Supply Status for the relevant Pharmaceutical and, where applicable, its listing on the Pharmaceutical Schedule; and (ii) a separate contract on the terms and conditions set out in: (A) your Tender Bid, to the extent applicable (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule); and for the Community Tender Bid element of Community/Hospital Tender Bid, Schedule Six; and that Combined

(B) (C)

if PHARMAC accepts a Foreign Exchange Bid from you, Schedule Seven,

will be deemed to have been entered into between you and PHARMAC for Sole Supply Status for the relevant Pharmaceutical and, where applicable, its listing on the Pharmaceutical Schedule. For the avoidance of doubt, the terms and conditions specified in Schedule Five, Schedule Six and Schedule Seven, as applicable, apply from the date when PHARMAC notifies you in accordance with clause 7.2 of this Schedule of its acceptance of your Tender Bid, and do not apply solely for the Sole Supply Period or Hospital Supply Status Period, as applicable.

1.4

Extension of Hospital Supply Status to include Sole Supply Status

(a) You acknowledge and agree that if your Hospital Tender Bid is for a Tender Item that is specified in the product list in clause 2 of Schedule Two as being a Tender Item for which you may submit a Tender Bid for Hospital Supply Status, you may agree (such consent not to be unreasonably withheld), if so requested by PHARMAC: (i) (ii) if PHARMAC has not yet accepted a Hospital Tender Bid for the particular Tender Item, to extend your Tender Bid to cover community supply; or if PHARMAC has accepted your Hospital Tender Bid for the particular Tender Item, to supply the Tender Item for use in the community under Sole Supply Status as soon as practicable after such requirement is notified to you, and in any case no later than three months after that notification, under a separate contract for Sole Supply Status.

R33-4-0 #94186

Schedule 3 (b) The Community Tender Bid referred to in paragraph (a)(i) above and the contract for Sole Supply Status referred to in paragraph (a)(ii) above will be: (i) (ii) at a price that is equal to the Price specified for that Pharmaceutical in your Hospital Tender Bid; and on the other terms and conditions set out in your Hospital Tender Bid (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule), as applicable; and for supply in accordance with Schedule Six; and for such quantities of the Pharmaceutical as are required for use in the community.

(iii) (iv) (c)

This clause confers a benefit on, and is enforceable by, the Funder in accordance with the Contracts (Privity) Act 1982.

1.5

Extension of Sole Supply Status to include Hospital Supply Status

(a) You acknowledge and agree that if your Community Tender Bid is for a Tender Item that is specified in the product list in clause 2 of Schedule Two as being a Tender Item for which you may submit a Tender Bid for Sole Supply Status, you may agree (such consent not to be unreasonably withheld), if so required by PHARMAC: (i) (ii) if PHARMAC has not yet accepted a Community Tender Bid for the particular Tender Item, to extend your Tender Bid to cover hospital supply; or if PHARMAC has accepted your Community Tender Bid for the particular Tender Item, to supply the Tender Item for use in DHB Hospitals under Hospital Supply Status as soon as practicable after such requirement is notified to you, and in any case no later than three months after that notification, under a separate contract for Hospital Supply Status.

(b)

The Hospital Tender Bid referred to in paragraph (a)(i) above and the contract for Hospital Supply Status referred to in paragraph (a)(ii) above will be: (i) (ii) at a price that is equal to the Price specified for that Pharmaceutical in your Community Tender Bid; and on the other terms and conditions set out in your Community Tender Bid (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule), as applicable; and for supply in accordance with Schedule Five; and for such quantities of the Pharmaceutical as are required for use in DHB Hospitals.

(iii) (iv) (c)

This clause confers a benefit on, and is enforceable by, DHB Hospitals in accordance with the Contracts (Privity) Act 1982.

R33-4-0 #94186

Schedule 3

1.6

PHARMAC may initiate limited negotiations

(a) Notwithstanding clause 2.7 of this Schedule, PHARMAC may, in its sole discretion, initiate negotiations or discussions with you in relation to your Tender Bid about: (i) (ii) (iii) (iv) any of the terms and conditions to apply if your Tender Bid is accepted; the proposed packaging or pack size of the Tender Item; your ability to ensure continued availability of the Tender Item throughout the Hospital Supply Status Period and/or Sole Supply Period, as applicable; the price of the Tender Item, but only where PHARMAC determines, in its sole discretion, that an increased price for the Tender Item may be necessary for practicality of supply of the Tender Item (for example, because of particular packaging requirements); DV Limits and/or DV Pharmaceuticals, in relation to hospital supply; the Lead Time and/or the Start Date; or any other matter that PHARMAC considers necessary or appropriate.

(v) (vi) (vii) (b)

If PHARMAC initiates negotiations or discussions with you under paragraph (a), and as a result there is a change to any of the terms and conditions relating to the supply of a Tender Item, PHARMAC is not obliged to inform the other tenderers of that change, nor give those tenderers an opportunity to amend their bid for that Tender Item. The initiation and pursuit of any negotiations or discussions under this clause shall not constitute a counter-offer and your original Tender Bid will remain open for acceptance in accordance with clause 4.2(b) of this Schedule in the absence of agreement on any variation to that Tender Bid.

(c)

1.7

Termination and amendment of Invitation

PHARMAC may: (a) (b) amend this Invitation at any time up to five business days before the Deadline; and/or terminate this Invitation at any time before the acceptance of any Tender Bid by giving five business days’ written notice.

2.1

Information about submitting a Tender Bid Choice of forms and strengths

Where a Tender Item includes different forms and strengths of a Chemical Entity or entities, your Tender Bid may, but does not need to, include all of the forms and strengths of the Chemical Entity or entities contained in that Tender Item.

2.2

Consents not yet held

You may submit a Tender Bid for a Tender Item where your brand of the Tender Item is yet to obtain all necessary Consents. In those circumstances, you may be required to demonstrate your ability to obtain those consents within a time frame acceptable to PHARMAC. For example, you may be required to demonstrate that you have the dossier for that brand of the

R33-4-0 #94186

Schedule 3 Tender Item ready to submit to Medsafe within one month of such a request being made by PHARMAC.

2.3

Individual Tender Bids

You may submit more than one bid for a Tender Item (for example, you may submit separate bids for different pack sizes of a Tender Item) provided that each bid is submitted on a separate Tender Submission Form.

2.4

Aggregated Tender Bids

(a) You may, in addition to submitting a separate Tender Bid for each Tender Item, submit an Aggregated Tender Bid, provided that: (i) (ii) (iii) (b) each brand contained in an Aggregated Tender Bid is only a different form